Vycor Medical (VYCO) POS AM30 Oct 13Prospectus update (post-effective amendment)Financial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	VYCOR MEDICAL INC
Entity Central Index Key	1424768
Amendment Flag	TRUE
Amendment Description	EXPLANATORY NOTE Vycor Medical, Inc., a Delaware corporation (the "Company"), filed a Registration Statement on September 7, 2011, on Form S-1, and subsequent amendments (the "Original Registration Statement") (SEC File Number 333-176713), which was declared effective November 10, 2011, for the purpose of registering 93,602,221 shares of common stock par value $0.0001 offered for sale by selling shareholders (the "Offering") under the Securities Act of 1933. The number of shares offered for sale was reduced to 615,597 following the January 15, 2013 effectiveness of a one-for-150 reverse stock split. All share amounts in this prospectus are adjusted to reflect the reverse stock split. On September 6, 2012, the Company filed a Post-Effective Amendment No. 1 to the Original Registration Statement on Form S-1 contained an updated prospectus relating to the offering and sale of shares of common stock declared effective by the Securities and Exchange Commission on November 10, 2011. On September 20, 2012, the Company filed a Post-Effective Amendment No. 2 solely to amend Exhibits 5.1 and 23.1 which were included in Post-Effective Amendment No. 1. This Post-Effective amendment No. 3 to the Original Registration Statement on Form S-1 contains an updated prospectus relating to the offering and sale of shares of common stock declared effective by the Securities and Exchange Commission on November 10, 2011. This Post-Effective Amendment No. 3 on Form S-1 is being filed to 1) extend our offering date until April 30, 2014, and 2) include the audited financial statements for the years ended December 31, 2012 and December 31, 2011 and unaudited financial statements for the interim periods ended June 30, 2013 and June 30, 2012. All filing fees payable in connection with the registration of the shares being registered hereby were previously paid in connection with the filing of the original registration statement.
Document Type	POS AM
Document Period End Date	30-Jun-13
Entity Filer Category	Smaller Reporting Company

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Current Assets
Cash	$20,173	$59,821	$950,841
Accounts receivable, net	92,182	144,347	313,679
Inventory	259,139	290,508	184,070
Prepaid expenses and other current assets	301,624	429,102	881,005
Total Current Assets	673,118	923,778	2,329,595
Fixed assets, net	721,777	827,389	671,291
Intangible and Other assets:
Trademarks	251,157	251,157	130,000
Patents, net of accumulated amortization	498,844	502,895	379,579
Website, net of accumulated amortization	2,016	2,772	4,906
Security deposits	53,169	53,169	56,269
Total Intangible and Other assets	805,186	809,993	570,754
TOTAL ASSETS	2,200,081	2,561,160	3,571,640
Current Liabilities
Accounts payable	237,553	187,789	176,181
Accrued interest	284,973	195,138	56,993
Accrued liabilities	1,390,395	1,198,463	754,895
Other current liabilities	85,427	241,918	72,122
Notes payable - current	2,610,198	2,195,502	1,636,125
TOTAL CURRENT AND TOTAL LIABILITIES	4,608,546	4,018,810	2,696,316
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 21.6, 39.3 and 62.8 issued and outstanding as at June 30, 2013, December 31, 2012 and December 31, 2011, respectively	1	1	1
Common Stock, $0.0001 par value, 1,500,000,000 shares authorized, 6,543,314, 6,020,555 and 5,381,358 shares issued and outstanding at June 30, 2013, December 31, 2012 and December 31, 2011, respectively	654	602	538
Additional Paid-in Capital	13,488,602	13,140,463	12,512,297
Treasury Stock (103,334 and 68,889 shares of Common Stock as at June 30, 2013 and December 31, 2012 respectively, at cost)	-1,033	-7
Accumulated Deficit	-15,898,412	-14,587,914	-11,661,704
Accumulated Other Comprehensive Income/Loss	1,723	-10,795	24,192
Total Stockholders' Equity (Deficit)	-2,408,465	-1,457,650	875,324
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$2,200,081	$2,561,160	$3,571,640

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Balance Sheets [Abstract]
Allowance for doubtful accounts receivable		$2,754	$0
Accumulated amortization, patents		202,767
Accumulated amortization, website		$16,137
Preferred Stock, par value (in dollars per share)	$0.00	$0.00	$0.00
Preferred Stock, Series C Convertible Preferred Stock, shares authorized	10,000,000	10,000,000	10,000,000
Preferred Stock, Series C Convertible Preferred Stock, shares issued	21.6	39.3	62.8
Preferred Stock, Series C Convertible Preferred Stock shares outstanding	21.6	39.3	62.8
Common Stock, par value (in dollars per share)	$0.00	$0.00	$0.00
Common Stock, shares authorized	1,500,000,000	1,500,000,000	1,500,000,000
Common Stock, shares issued	6,543,314	6,020,555	5,381,358
Common Stock, shares outstanding	6,543,314	6,020,555	5,381,358
Treasury Stock, shares	103,334	68,889

Consolidated_Statement_of_Oper

Consolidated Statement of Operations (Audited) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
Consolidated Statement of Operations (Audited) (USD $)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Statement Of Operations [Abstract]
Revenue	$234,954	$265,386	$466,628	$697,987	$1,205,263	$971,367
Cost of Goods Sold	27,894	40,248	57,912	119,669	179,530	176,258
Gross Profit	207,060	225,138	408,716	578,318	1,025,733	795,109
Operating expenses:
Research and development	21,285	45,860	52,635	70,547	126,042	115,665
Depreciation and Amortization	89,276	82,590	175,546	164,166	328,890	209,973
General and administrative	706,111	839,407	1,389,769	1,894,380	3,413,004	4,987,120
Negative Goodwill on Acquisition of Subsidiary				-66,394	-66,394
Costs related to Acquisition of Subsidiary				18,285	18,285	110,032
Total Operating expenses	816,672	967,857	1,617,950	2,080,984	3,819,827	5,422,790
Operating loss	-609,612	-742,719	-1,209,234	-1,502,666	-2,794,094	-4,627,681
Other income (expense)
Other income (expense)	8,725	-23,336	-11,433	-15,219	5,815	-23,718
Interest expense	-46,939	-31,679	-89,831	-63,279	-137,931	-127,142
Total Other expense	-38,214	-55,015	-101,264	-78,498	-132,116	-150,860
Loss Before Income Taxes					-2,926,210	-4,778,541
Income Taxes
Net loss	($647,826)	($797,734)	($1,310,498)	($1,581,164)	($2,926,210)	($4,778,541)
Net Loss Per Common Share
Basic and diluted	($0.10)	($0.14)	($0.21)	($0.28)	($0.52)	($0.92)
Weighted Average Number of Shares Outstanding	6,264,362	5,660,498	6,107,053	5,607,358	5,637,690	5,200,645

Statement_of_Stockholders_Equi

Statement of Stockholders' Equity (Deficiency) and Comprehensive Income (USD $)	Total	Common Stock	Preferred Stock - Series C	Treasury Shares [Member]	Additional Paid-in Capital	Accumulated Deficit	Accumulated OCI (Loss)
Beginning Balance at Dec. 31, 2010	$88,714	$483	$0	$0	$6,974,393	($6,883,163)	($2,999)
Beginning Balance, Shares at Dec. 31, 2010		4,829,904		0
Issuance of stock for consulting fees	856,225	26			856,199
Issuance of stock for consulting fees, shares		263,043
Share-based compensation for consulting services	699,605				699,605
Share-based compensation - employee options vesting	29,796				29,796
Purchases of equity - Common stock	889,000	27			888,973
Purchases of equity - Common stock, shares		271,271
Purchases of equity - Series C preferred	2,971,456		1		2,971,455
Common stock issuance for conversion of debt	41,190	1			41,189
Common stock issuance for conversion of debt, shares		14,453
Common stock issuance for warrant exercise	443	1			442
Common stock issuance for warrant exercise, shares		2,687
Preferred Stock issue placement agent warrants	50,245				50,245
Accumulated Comprehensive Loss	27,191						27,191
Net loss	-4,778,541					-4,778,541
Balance at Dec. 31, 2011	875,324	538	1	0	12,512,297	-11,661,704	24,192
Balance, Shares at Dec. 31, 2011		5,381,358		0
Issuance of stock for consulting fees	379,381	27			379,354
Issuance of stock for consulting fees, shares		267,969
Share-based compensation for consulting services	8,708				8,708
Cancellation of share-based compensation	-232,499				-232,499
Purchases of equity - Common stock	170,000	5			169,995
Purchases of equity - Common stock, shares		50,372
Settlement - Common Stock	0	-14			14
Settlement - Common Stock, shares		-137,778
Repurchase of equity into Treasury Stock	-1,033	-7		-7	-1,026
Repurchase of equity into Treasury Stock, shares		-68,889		-68,889
Common stock issuance for conversion of preferred shares	0	35			-35
Common stock issuance for conversion of preferred shares, shares		348,152
Common stock issuance for charitable donation	16,667	1			16,666
Common stock issuance for charitable donation, shares		14,815
Issuance of stock for acquisition	287,000	10			286,990
Issuance of stock for acquisition, shares		95,667
Accumulated Comprehensive Loss	-34,987						-34,987
Net loss	-2,926,210					-2,926,210
Balance at Dec. 31, 2012	($1,457,650)	$602	$1	($7)	$13,140,463	($14,587,914)	($10,795)
Balance, Shares at Dec. 31, 2012		6,020,555		-68,889

Statement_of_Cash_Flows_Audite

Statement of Cash Flows (Audited) (USD $)	6 Months Ended		12 Months Ended
Statement of Cash Flows (Audited) (USD $)	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:
Net loss	($1,310,498)	($1,581,164)	($2,926,210)	($4,778,541)
Adjustments to reconcile net loss to cash used in operating activities:
Amortization of intangible assets	62,844	51,546	104,344	69,022
Depreciation of fixed assets	126,512	123,320	247,156	161,284
Share based compensation and expense	174,064	204,755	297,004	1,760,545
Changes in assets and liabilities:
Accounts receivable	51,887	141,390	169,729	-237,294
Inventory	31,329	-145,473	-106,396	-131,872
Prepaid expenses	-4,129	177,296	256,095	-412,254
Security deposit			3,100	-43,970
Accounts payable	49,853	-18,567	11,477	62,560
Accrued interest	89,835	63,448	138,145	21,191
Accrued liabilities	193,548	218,114	431,700	349,906
Other current liabilities	-16,302	51,891	2,926	-15,911
Cash used in operating activities	-551,057	-713,444	-1,370,930	-3,195,334
Cash flows used in investing activities:
Purchase of fixed assets	-20,116	-17,635	-28,177	-61,995
Purchase of website				-3,360
Acquisition of subsidiary, net of cash acquired	-139,153	-153,641	-153,641
Acquisition of patents	-58,457	-16,077	-33,333	-110,406
Cash used in investing activities	-217,726	-187,353	-215,151	-175,761
Cash flows from financing activities:
Proceeds from issuance of Common stock, net	304,351	120,000	170,000	889,443
Net proceeds from issuance of Series B preferred				3,021,700
Purchase of shares into Treasury Stock		-1,033	-1,033
Net proceeds from issuance of Notes Payable	442,962	15,863	610,594	543,105
Repayment of Notes Payable	-28,236	-26,528	-51,193	-280,822
Cash provided by (used in) financing activities	719,077	108,302	-728,368	4,173,426
Effect of exchange rate changes on cash	10,058	11,311	-33,307	21,429
Net increase (decrease) in cash	-39,648	-781,184	-891,020	823,760
Cash at beginning of period	59,821	950,841	950,841	127,081
Cash at end of period	20,173	169,657	59,821	950,841
Supplemental Disclosures of Cash Flow information:
Interest paid:		197	207	1,686
Taxes paid
Non-Cash Transactions:
Common stock issued on conversion of Preferred C shares	885,000	900,000
Acquisition of subsidiary, net of cash acquired
Trademarks and Tradenames		121,157	121,157
Patents		180,183	180,183
Internally Developed Software		363,472	363,472
Other Net Assets		-758	-758
Negative Goodwill on Acquisition		-66,394	-66,394
Total assets acquired		597,660	597,660
Warrants, options and common stock issued for acquisition of subsidiary		-287,000	-287,000
Deferred consideration payable	139,153	-155,330	-161,530
Foreign exchange difference on deferred consideration	0	-1,689	4,511
Acquisition of newly acquired subsidiary, net of cash	$139,153	$153,641	$153,641

Basis_of_Presentation

Basis of Presentation	6 Months Ended
Basis of Presentation	Jun. 30, 2013
Basis of Presentation and Formation and Business of the Company [Abstract]
BASIS OF PRESENTATION	1. BASIS OF PRESENTATION

	The consolidated financial statements of the Company present the financial position, results of operations, and cash flows of Vycor Medical, Inc. and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive financial statements have been condensed or omitted pursuant to such rules and regulations. The consolidated balance sheet as of December 31, 2012 derives from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012.

	The condensed consolidated financial statements for the three and six months ended June 30, 2013 and 2012, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company's financial condition and results of operations. The results of operations for the three months and six months ended June 30, 2013 and 2012 are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Certain prior period amounts have been reclassified to conform to the current presentation.

Formation_and_Business_of_the_

Formation and Business of the Company	6 Months Ended	12 Months Ended
Formation and Business of the Company	Jun. 30, 2013	Dec. 31, 2012
Basis of Presentation and Formation and Business of the Company [Abstract]
FORMATION AND BUSINESS OF THE COMPANY	2. FORMATION AND BUSINESS OF THE COMPANY
		1. FORMATION AND BUSINESS OF THE COMPANY
	Business Description
		Business Description
	Vycor Medical, LLC was formed on June 17, 2005 as a New York Limited Liability Company. The Company changed its name to Vycor Medical, Inc. and converted to a Delaware Corporation on August 14, 2007 and issued 107 shares of common stock in exchange for each of the 1,122 partnership units outstanding at date of conversion. The assets, liabilities and operations of the Company did not change pursuant to this reorganization, and the accompanying financial statements are presented as if the change occurred on the first day of the earliest period presented. Accordingly, all references to number of shares prior to the date of conversion are based upon the common stock equivalent of the partnership units outstanding on such dates.
		Vycor Medical, LLC was formed on June 17, 2005 as a New York Limited Liability Company. The Company changed its name to Vycor Medical, Inc. and converted to a Delaware Corporation on August 14, 2007 and issued 16,048 shares of common stock in exchange for each of the 1,122 partnership units outstanding at date of conversion. The assets, liabilities and operations of the Company did not change pursuant to this reorganization, and the accompanying financial statements are presented as if the change occurred on the first day of the earliest period presented. Accordingly, all references to number of shares prior to the date of conversion are based upon the common stock equivalent of the partnership units outstanding on such dates.
	The Company designs, develops and markets neurological medical devices and therapies through two operating divisions: Vycor Medical and NovaVision. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals; NovaVision focuses on neuro-stimulation therapies and diagnostic devices for the treatment and screening of vision field loss.
		The Company designs, develops and markets neurological medical devices and therapies through two operating divisions: Vycor Medical and NovaVision. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals; NovaVision focuses on neuro-stimulation therapies and diagnostic devices for the treatment and screening of vision field loss resulting from neurological damage.

Going_Concern

Going Concern	6 Months Ended	12 Months Ended
Going Concern	Jun. 30, 2013	Dec. 31, 2012
Going Concern [Abstract]
GOING CONCERN	3. GOING CONCERN	2. GOING CONCERN

	The Company's financial statements have been presented on a basis that contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and assumes the Company will continue as a going concern. The Company has incurred losses since its inception, including a net loss of $1,310,498 for the six months ended June 30, 2013, and the Company expects to incur additional losses. The Company has generated negative cash flows from operations since inception. As of June 30, 2013, current liabilities exceeded current assets by $3,935,428 the Company had a stockholders' deficit of $2,408,465 and cash and cash equivalents of $20,173. The Company believes it will not have enough cash to meet its various cash needs unless the Company is able to obtain additional cash from the issuance of debt or equity securities. The Company intends to raise funds from the issuance of equity and/or debt securities, but there is no assurance that additional funds from the issuance of equity will be available for the Company to finance its operations on acceptable terms, or at all. If adequate funds are not available, the Company may have to delay development or commercialization of products or technologies that the Company would otherwise seek to commercialize, or cease operations. These conditions, among others, raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.	The Company’s financial statements have been presented on a basis that contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and assumes the Company will continue as a going concern. The Company has incurred losses since its inception, including a net loss of $2926,210 for the year months ended December 31, 2012, and the Company expects to incur additional losses. The Company has generated negative cash flows from operations since inception. As of December 31, 2012, current liabilities exceeded current assets by $3,095,031 the Company had a stockholders’ deficit of $1,457,650 and cash and cash equivalents of $59,821. The Company believes it will not have enough cash to meet its various cash needs unless the Company is able to obtain additional cash from the issuance of debt or equity securities. The Company intends to raise funds from the issuance of equity and/or debt securities, but there is no assurance that additional funds from the issuance of equity will be available for the Company to finance its operations on acceptable terms, or at all. If adequate funds are not available, the Company may have to delay development or commercialization of products or technologies that the Company would otherwise seek to commercialize, or cease operations. These conditions, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

Business_Acquisition

Business Acquisition	12 Months Ended
	Dec. 31, 2012
Business Acquisition [Abstract]
BUSINESS ACQUISITION
	3. BUSINESS ACQUISITION

	On January 4, 2012, the Company completed its acquisition (the “Acquisition”) of all of the shares of Sight Science Limited (“Sight Science”) in the UK, a company that is in the business of researching, developing and providing medical technologies to restore the vision of patients with neurological visual loss. The total consideration to the Sight Science shareholders was £384,768 (US$597,660); comprising: £200,000 (US$ 310,660) cash, of which £100,000 (US$155,330) was paid at the Closing and an additional £100,000 (US$155,330) cash to be paid to the Sight Science shareholders on the one-year anniversary of the Closing; an aggregate of 95,667 restricted shares of the Company (14,350,000 pre-split), which are the subject of lock-up agreements between the Parties and which at Closing were valued at £184,768 (US$287,000). In

	January, 2012 the Parties agreed to a rescheduling of the deferred consideration due on January 4, 2013 to be paid over the course of the six months from January to June 2013

	As required under Financial Accounting Standards Board Accounting Standards Codification (“ASC”) 805, Business Combinations, the Company commissioned an independent appraisal of the assets acquired which was finalized in March 2012. The Company determined the fair value of the assets acquired pursuant to the acquisition method as defined in ASC 805 and ASC 350, Intangibles-Goodwill and Other. Included in this valuation were assumptions concerning the cost of equity determined via the build-up method, the cost of debt and the weighted average cost of capital. Cash flows as included in the valuation were projected based on historical operations as well as management’s projections for future results based on these historical amounts. The trademark and patent valuations were based upon the Relief-from Royalty Method on an after tax basis. The value of the Internally Developed Software was based upon the Multi-period Excess Earnings Method utilizing, among other factors, a discount rate based on the Weighted Average Cost of Capital.

	As a result, the Company generated negative goodwill on the acquisition of $66,394 which has been recorded in the Consolidated Statement of Operations for the year ended December 31, 2012.

	The expenses of the transaction, which primarily comprised legal fees and audit fees in connection with the Form 8-K/A filed on March 21, 2012 and the ASC 805 valuation amounted to $18,285.

	The following table represents the final purchase price allocation to the estimated fair value of the assets acquired and liabilities assumed:

		Amount

	Trademarks and Tradenames	$	121,157
	Patents		180,183
	Internally Developed Software		363,472
	Other Net Assets		(758	)
			664,054
	Negative Goodwill on acquisition		(66,394	)
	Purchase Price	$	597,660

	Assuming the acquisition discussed above had occurred on January 1, 2011, for the year ended December 31, 2011, pro forma revenues, net loss and net loss per share for the Company would have been $1,001,624 $(4,743,324) and $(0.896), respectively.

	The pro forma results are not necessarily indicative of the operating results that would have been obtained had the acquisitions occurred at the beginning of the period presented, nor are they necessarily indicative of future operating results.

	Deferred Consideration

	As stated above, £100,000 of the cash consideration is deferred for payment in monthly installments from January to June 2013. This is recorded in Other Current Liabilities and at December 31, 2012 amounted to $161,530.

Significant_Accounting_Policie

Significant Accounting Policies

6 Months Ended

12 Months Ended

Jun. 30, 2013

Dec. 31, 2012

Significant Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

4. SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. NovaVision GmbH was converted from an AG on July 4, 2012. The Company is headquartered in Boca Raton, FL. The operations of Sight Science have been consolidated since January 4, 2012 the date of the completion of the acquisition of all the shares of Sight Science. All material inter-company accounts, transactions, and profits have been eliminated in consolidation.

Recent Accounting Pronouncements

Revenue Recognition

From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company's accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.

Vycor Medical generates revenue from the sale of its surgical access system to hospitals and other medical professionals. Vycor Medical records revenue when a completed contract for the sale exists, the product is invoiced and shipped to the customer. Vycor Medical does provide for product returns or warranty costs.

Net Loss Per Share

NovaVision generates revenues from various programs, therapy services and other sources such as license sales. Therapy services revenues represent fees from NovaVision’s vision restoration therapy software, diagnostic software, medical devices, clinic set up and training fees, and the professional and support services associated with the therapy. NovaVision recognizes revenue for providing the vision restoration therapy as the Company’s work effort is expended. NovaVision provides vision restoration therapy directly to patients. The typical vision restoration therapy consists of six modules, performed on average over 6 months in the U.S. and 10 months in Germany. A patient contract comprises set-up fees and monthly therapy fees. Set-up fees are recognized at the outset of the contract and therapy revenue is recognized ratably over the therapy period. Patient therapy is restricted to being completed by a patient within a specified time frame.

Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.

Deferred revenue results from patients paying for the therapy in advance of receiving the therapy.

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:

Accounts Receivable and Allowance for Doubtful Accounts Receivable

We have a policy of reserving for uncollectible accounts based on our best estimate of the amount of probable credit losses in our existing accounts receivable. We extend credit to our customers based on an evaluation of their financial condition and other factors. We generally do not require collateral or other security to support accounts receivable. We perform ongoing credit evaluations of our customers and maintain an allowance for potential bad debts if required. We determine whether an allowance for doubtful accounts is required by evaluating specific accounts where information indicates the customers may have an inability to meet financial obligations. In these cases, we use assumptions and judgment, based on the best available facts and circumstances, to record a specific allowance for those customers against amounts due to reduce the receivable to the amount expected to be collected. These specific allowances are re-evaluated and adjusted as additional information is received. The amounts calculated are analyzed to determine the total amount of the allowance. We may also record a general allowance as necessary. Direct write-offs are taken in the period when we have exhausted our efforts to collect overdue and unpaid receivables or otherwise evaluate other circumstances that indicate that we should abandon such efforts.

June 30,

Inventories

2013

2012

Stock options outstanding

5,557

Inventories are stated at the lower of cost, determined using the weighted average cost method, and net realizable value. Net realizable value is the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose of the product.

Warrants to purchase common stock

1,423,123

1,745,207

Debentures convertible into common stock

368,727

368,726

If the Company identifies excess, obsolete or unsalable items, its inventories are written down to their realizable value in the period in which the impairment is first identified. Shipping and handling costs incurred for inventory purchases and product shipments are recorded in cost of sales in the Company's consolidated statements of operations.

Preferred shares convertible into common stock

320,007

663,719

Total

2,117,414

2,783,209

Property and equipment

Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.

Impairment of long lived assets

Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not be recoverable. For assets that are to be held and used, impairment is recognized when the estimated undiscounted cash flows associated with the asset or group of assets is less than their carrying value. If impairment exists, an adjustment is made to write the asset down to its fair value, and a loss is recorded as the difference between the carrying value and fair value. Fair values are determined based on quoted market values, discounted cash flows or internal and external appraisals, as applicable. Assets to be disposed of are carried at the lower of carrying value or estimated net realizable value.

Research and Development

The Company expenses all research and development costs as incurred. For the years ended December 31, 2012 and 2011, the amounts charged to research and development expenses were $126,042 and $115,665, respectively.

Software Development Costs

The authoritative accounting guidance requires software development costs to be capitalized upon completion of the preliminary project stage. Accordingly, direct internal and external costs associated with the development of the features and functionality of the Company’s software, incurred during the application development stage, are capitalized and amortized using the straight-line method of the estimated life of five years. The Company acquired internally developed software valued at $540,000 as part of the acquisition of the assets of NovaVision, Inc. on November 30, 2010 and $363,472 as part of the acquisition of the assets of Sight Science Limited on January 4, 2012. For the years ended December 31, 2012 and 2011 there was no capitalization of software development costs.

Uses of estimates in the preparation of financial statements

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimated. To the extent management’s estimates prove to be incorrect, financial results for future periods may be adversely affected. Significant estimates and assumptions contained in the accompanying consolidated financial statements include management’s estimate of the allowance for uncollectible accounts receivable, amortization of intangible assets, and the fair values of options and warrants included in the determination of debt discounts and share based compensation.

Stock Compensation

The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for under in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.

Convertible Instruments

We evaluate and account for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”.

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

We account for convertible instruments (when we have determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: We record when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The embedded conversion option in connection with our convertible debt could not be exercised unless and until we completed a Qualifying Financing transaction. Accordingly, we determined based on authoritative guidance that the embedded conversion option is deemed to be a contingent conversion rather than active conversion option that did not require accounting recognition at the commitment dates of the issuances of the Notes.

Common Stock Purchase Warrants and Other Derivative Financial Instruments

We classify as equity any contracts that require physical settlement or net-share settlement or provide us a choice of net-cash settlement or settlement in our own shares (physical settlement or net-share settlement) provided that such contracts are indexed to our own stock as defined in ASC 815-40 ("Contracts in Entity's Own Equity"). We classify as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside our control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). We assess classification of our common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.

Fair Value Measurements

We adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short and long term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

Net Loss Per Share

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:

December 31,

2012

2011

Stock options outstanding

5,557

Warrants to purchase common stock

1,749,874

1,747,347

Debentures convertible into common stock

368,726

Preferred shares convertible into common stock

582,233

930,382

Total

2,706,390

3,052,012

Recent Accounting Pronouncements

From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.

Notes_Payable

Notes Payable	6 Months Ended						12 Months Ended
Notes Payable	Jun. 30, 2013						Dec. 31, 2012
Notes Payable [Abstract]
NOTES PAYABLE	5. NOTES PAYABLE						5. NOTES PAYABLE

	As of June 30, 2013 and December 31, 2012 Notes Payable consists of:						As of December 31, 2012 and 2011 Notes Payable consists of:

								31-Dec-12		31-Dec-12
							On December 29, 2009 and February 3, 2010, the Company issued convertible debentures in the amount of $371,362 and $70,000, respectively, payable to Fountainhead Capital Management (“Fountainhead”), the beneficial owner of more than 50% of the Company’s common stock. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $1.88 per share, subject to adjustment and does not require bifurcation. These debentures were originally due August 31, 2010 and the due date has been extended over time to December 31, 2013.		441,362		441,362
				June 30,		December 31,
				2013		2012	On September 30, 2010 and October 14, 2010, the Company issued convertible debentures payable to Fountainhead in the amount of $85,000 and $90,000, respectively. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $2.63 per share, subject to adjustment and does not require bifurcation. The debentures were originally due August 31, 2011, and the due date has been extended over time to December 31, 2013.		175,000		175,000
		On December 29, 2009 and February 3, 2010, the Company issued convertible debentures in the amount of $371,362 and $70,000, respectively, payable to Fountainhead Capital Management ("Fountainhead"), the beneficial owner of more than 50% of the Company's common stock. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $1.88 per share, subject to adjustment and does not require bifurcation. These debentures were originally due August 31, 2010 and the due date has been extended over time to December 31, 2013		441,362		441,362
							On October 26, 2010 and November 15, 2010, the Company issued debentures payable to Fountainhead in the amount of $77,500 and $322,500, respectively. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The debentures were originally due August 31, 2011, and the due date has been extended over time to December 31, 2013.		400,000		400,000

							On November 15, 2010, the Company issued a convertible debenture in the amount of $350,000 payable to Peter Zachariou, a Director of the Company. This debenture accrues interest rate of 6% per annum, is due on December 31, 2012, is secured by a first priority security interest in all of the assets of the Company, and is senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debenture then outstanding into shares of common stock of the Company at the conversion price of $2.85 per share, subject to adjustment and does not require bifurcation. On December 20, 2010, the Company repaid $50,000 of this debenture and removed the convertible rights. The debentures were originally due December 31, 2012 and the due date has been extended over time to December 31, 2013.		300,000		300,000

		On September 30, 2010 and October 14, 2010, the Company issued convertible debentures payable to Fountainhead in the amount of $85,000 and $90,000, respectively. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $2.63 per share, subject to adjustment and does not require bifurcation. The debentures were originally due August 31, 2011, and the due date has been extended over time to December 31, 2013.		175,000		175,000	On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011. In connection with the loan the Company also issued EuroAmerican warrants to purchase 2,667 shares of the Company’s common stock at an exercise price of $4.50 per share for a period of three (3) years. On June 25, 2011 the due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company at the conversion price of $4.50 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended over time to June 30th, 2013		300,000		300,000

		On October 26, 2010 and November 15, 2010, the Company issued debentures payable to Fountainhead in the amount of $77,500 and $322,500, respectively. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The debentures were originally due August 31, 2011, and the due date has been extended over time to December 31, 2013.		400,000		400,000	In the period July to December 2012 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $300,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		300,900		-

		On November 15, 2010, the Company issued a convertible debenture in the amount of $350,000 payable to Peter Zachariou, a Director of the Company. This debenture accrues interest rate of 6% per annum, is secured by a first priority security interest in all of the assets of the Company, and is senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debenture then outstanding into shares of common stock of the Company at the conversion price of $2.85 per share, subject to adjustment and does not require bifurcation. On December 20, 2010, the Company repaid $50,000 of this debenture and removed the convertible rights. The debentures were originally due December 31, 2012 and the due date has been extended over time to December 31, 2013.		300,000		300,000	In the period August to December 2012 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $115,500. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		115,500		-

		On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. ("EuroAmerican"). The term note bears interest at 16% per annum and was due June 25, 2011. In connection with the loan the Company also issued EuroAmerican warrants to purchase 400,000 shares of the Company's common stock at an exercise price of $4.50 per share for a period of three (3) years. On June 25, 2011 the due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company at the conversion price of $4.50 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended over time to September 30, 2013		300,000		300,000	In the period August to December 2012 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $98,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		98,550		-

		In the period July to December 2012 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $300,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		300,900		300,900	In September 2012 the Company issued short term, unsecured notes payable to Osbaldo Trading Limited in the amount of $42,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		42,900		-

		In the period August to December 2012 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $115,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		115,550		115,550	Unsecured, non-interest bearing loan from the chief executive of NovaVision AG, advanced a total of €8,250 to NovaVision AG, repayable in monthly installments. As of June 30, 2012 the loan had been repaid in full and December 31, 2011 the remaining balance was €8,250.		-		10,660

		In the period August to December 2012 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $98,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		98,550		98,550	Insurance policy finance agreements		21,290		9,103

							Total Notes Payable:	$	2,195,502	$	1,636,125

							As of December 31, 2012, $1,316,362 of Company's notes payable are secured by a first security interest in all of the assets of the Company. The company assesses the value of the beneficial conversion feature of its convertible debt by determining the intrinsic value of such conversion, under ASC 470, at the time of issuance. At the time of issuance of each of the convertible debt instruments set out above, the fair value of the stock was either the same or less than the conversion price, and so there was no value attributable to any beneficial conversion feature.
		In September 2012 the Company issued short term, unsecured notes payable to Osbaldo Trading Limited in the amount of $42,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		42,900		42,900

		In the period January to June 2013 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $234,225. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		234,225		-

		In the period January to June 2013 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $190,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		190,000		-

		Insurance policy finance agreements. During the six months ended June 30, 2013 the Company received proceeds from Insurance policy finance agreement of $18,737 and made repayments of $28,236		11,711		21,210

		Total Notes Payable:	$	2,610,198	$	2,195,502

	As of June 30, 2013, $1,316,362 of Company's notes payable is secured by a security interest in all of the assets of the Company. The company assesses the value of the beneficial conversion feature of its convertible debt by determining the intrinsic value of such conversion, under ASC 470, at the time of issuance. At the time of issuance of each of the convertible debt instruments set out above, the fair value of the stock was either the same or less than the conversion price, and so there was no value attributable to any beneficial conversion feature.

Segment_Reporting_Geographical

Segment Reporting, Geographical Information	6 Months Ended										12 Months Ended
Segment Reporting, Geographical Information	Jun. 30, 2013										Dec. 31, 2012
Segment Reporting, Geographical Information [Abstract]
SEGMENT REPORTING, GEOGRAPHICAL INFORMATION	6. SEGMENT REPORTING, GEOGRAPHICAL INFORMATION										6. SEGMENT REPORTING, GEOGRAPHICAL INFORMATION
	(a) Business segments
	The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss and which includes Sight Science. Set out below are the revenues, gross profits and total assets for each segment.										(a) Business segments

				Three Months Ended June 30,				Six Months Ended June 30,			The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss. Set out below are the revenues, gross profits and total assets for each segment.
				2013		2012		2013		2012
		Revenue:										December 31,
		Vycor Medical	$	146,358	$	138,239	$	277,024	$	460,021		2012		2011
		NovaVision		88,596		127,147		189,604		237,966	Revenue:
		Total Revenue	$	234,954	$	265,386	$	466,628	$	697,987	Vycor Medical	$	770,676	$	548,463
		Gross Profit:									NovaVision		434,587		422,904
		Vycor Medical	$	135,152	$	118,206	$	251,431	$	378,795	Total Revenue	$	1,205,263	$	971,367
		NovaVision		71,908		106,932		157,285		199,523	Gross Profit:
		Total Gross Profit	$	207,060	$	225,138	$	408,716	$	578,318	Vycor Medical		668,729		439,422
											NovaVision		357,004		355,687
											Total Gross Profit	$	1,025,733	$	795,109
				June 30,		December 31,
				2013		2012						December 31,
		Total Assets:										2012		2011
		Vycor Medical	$	859,185	$	1,055,026					Total Assets:
		NovaVision		1,340,896		1,506,134					Vycor Medical		1,055,026		2,068,084
		Total Assets	$	2,200,081	$	2,561,160					NovaVision		1,506,134		1,503,556
	(b) Geographic information										Total Assets		2,561,160	$	3,571,640
	The Company operates in two geographic segments, the United States and Europe. Set out below are the revenues, gross profits and total assets for each segment.
											(b) Geographic information. The Company operates in two geographic segments, the United States and Europe. Set out below are the revenues, gross profits and total assets for each segment.
				Three Months Ended June 30,				Six Months Ended June 30,
				2013		2012		2013		2012		December 31,
		Revenue:										2012		2011
		United States	$	180,792	$	205,602	$	360,307	$	567,850	Revenue:
		Europe		54,162		59,784		106,321		130,137	United States	$	952,256	$	740,967
		Total Revenue	$	234,954	$	265,386	$	466,628	$	697,987	Europe		253,007		230,400
		Gross Profit:									Total Revenue	$	1,205,263	$	971,367
		United States	$	161,140	$	172,994	$	317,328	$	463,764	Gross Profit:
		Europe		45,920		52,144		91,388		114,554	United States	$	810,809	$	607,702
		Total Gross Profit	$	207,060	$	225,138	$	408,716	$	578,318	Europe		214,924		194,651
											Total Gross Profit	$	1,025,733	$	802,353
											Total Assets:
				June 30,		December 31,					United States	$	2,475,933	$	3,470,993
				2013		2012					Germany		85,227		100,647
		Total Assets:									Total Assets		2,561,160	$	3,571,640
		United States	$	1,650,219	$	1,935,638
		Europe		549,862		625,523
		Total Assets	$	2,200,081	$	2,561,160

Property_and_Equipment

Property and Equipment	12 Months Ended
Property and Equipment	Dec. 31, 2012
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	7. PROPERTY AND EQUIPMENT

	As of December 31, 2012 and 2011, Property and Equipment and the estimated lives used in the computation of depreciation are as follows:

		Estimated	December 31,			December 31,
		Useful Lives	2012			2011

	Machinery and equipment	3 years		123,355		$	106,368
	Leasehold Improvements	5 years		6,206			-
	Purchased Software	3 years		17,833			15,607
	Molds and Tooling	5 years		234,230			234,230
	Furniture and fixtures	7 years		21,533			21,130
	Therapy Devices	3 years		76,513			59,065
	Internally Developed Software	5 years		923,215			559,304
				1,402,885			995,704

	Less: Accumulated depreciation and amortization			(575,496	)		(324,413	)

	Property and Equipment, net		$	827,389		$	671,291

	Depreciation expense for the years ended December 31, 2012 and 2011 was $247,156 and $157,676 respectively, including $22,610 and $16,725 respectively for Therapy Devices which is allocated to Cost of Sales.

Intangible_Assets

Intangible Assets	12 Months Ended
Intangible Assets	Dec. 31, 2012
Intangible Assets [Abstract]
INTANGIBLE ASSETS	8. INTANGIBLE ASSETS

	As of December 31, 2012 and 2011, Intangible Assets consists of:

		December 31,
		2012			2011
	Amortized intangible assets: Patent (8 years useful life)
	Gross carrying Amount	$	705,662		$	492,147
	Accumulated Amortization		(202,767	)		(112,568	)
		$	502,895		$	379,579

	Amortized intangible assets: Website (5 years useful life)
	Gross carrying Amount	$	18,909		$	18,909
	Accumulated Amortization		(16,137	)		(14,003	)
		$	2,772		$	4,906

	Intangible assets not subject to amortization
	Trademarks		251,157			130,000

	Intangible asset amortization expense for the periods ended December 31, 2012 and 2011 was $104,344 and $69,022, respectively.

Equity

Equity	6 Months Ended	12 Months Ended
Equity	Jun. 30, 2013	Dec. 31, 2012
Equity [Abstract]
EQUITY	7. EQUITY	9. EQUITY

	Certain Equity Transactions	Certain Equity Transactions

	During January to June 2013 the Company issued: 4,114 shares of Common Stock (valued at $10,000) to Steven Girgenti, 4,787 shares of Common Stock (valued at $10,000) to Dr. Oscar Bronsther and $1,078 shares of Common Stock (valued at $2,500) to Lowell Rush in consideration for services provided to the Board of Directors; and 1,594 shares of Common Stock (valued at $4,688) to Alvaro Pascual-Leone, 2,261 shares of Common Stock (valued at $6,250) to Josef Zihl and 2,319 shares of Common Stock (valued at $4,688) to Jason Barton and Jose Romano in respect of their roles as members of the NovaVision, Inc. Scientific Advisory Board.	In January and February 2011, the Company issued an aggregate of 50,527 shares of common stock to three investors at a price of $2.85 per share for aggregate gross proceeds of $144,000.

	On January 11, 2013, the Company filed a Certificate of Amendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split of 1 for 150 on the issued and outstanding Common Stock par value $0.0001 ("Common Stock"). On January 15, 2013 (the "Effective Date"), the Company effectuated its reverse stock split. On the Effective date, the Company implemented a one for 150 share reverse split of its Common Stock. On the Effective Date, the Company's pre-split 892,749,897 shares of Common Stock became 5,951,744 post-split shares of Common Stock, including the issuance of 66 shares of Common Stock for the round-up of partial shares. In connection with the reverse split, the Company's authorized capital was not changed. All relevant information relating to the number of shares and per share information has been retrospectively adjusted to reflect the reverse stock split for all periods presented.	During the period from January 1, 2011 through December 31, 2011, the Company issued 5,920 shares of Common Stock (valued at $20,000) to Steven Girgenti and 645 shares of Common Stock (valued at $2,174) Dr Oscar Bronsther in consideration for services provided to the Board of Directors; and 1,217 shares of Common Stock (valued at $6,250) to Alvaro Pasual-Leone, and 926 shares of Common Stock (valued at $6,250) to each of Jason Barton and Jose Romano, in respect of their roles as members of the NovaVision, Inc. Scientific Advisory Board.

	In March 2013 GreenBridge Capital Partners, IV, LLC returned to Vycor all of the 34,445 shares being sought by the Company under an action filed by the Company in July 2012. These shares have been taken into Treasury Stock.	On March 2, 2011, the Company issued warrants to seven parties to purchase 98,070 shares of the Company's common stock at a price of $4.50 per share. The warrants are exercisable over a period of three years from the date of issuance.

	During April and May 2013, the Company issued 47,590 and 32,152 shares of Common Stock respectively on exercise of warrants by Kenneth Coviello and Heather Vinas. The warrants had an exercise price of $1.08 and were exercisable on a cashless basis.	On March 25, 2011, in connection with the issuance by the Company of a term note for $300,000 to EuroAmerican Investment Corp, the Company issued warrants to purchase 2,667 shares of Company common stock at an exercise price of $4.50 per share for a period of three years from the date of issuance. The estimated fair value of this warrant was recorded as a debt discount at issuance and was amortized over the three-month term of the loan as interest expense.

	During April and May 2013, Fountainhead Capital Management sold 162,250 warrants to purchase Vycor Common Stock at an exercise price of $1.88 per share. These warrants were granted to Fountainhead by the Company in February 2010 and were sold by Fountainhead to 6 investors at a price of $0.10 per warrant. The warrants were immediately exercised by the investors and the Company issued 162,250 shares of Common Stock in respect of the exercise and received cash proceeds of $304,351.	In April 2011, the Company issued 162,965 shares of common stock together with Warrants to purchase 81,842 shares of common stock at an exercise price of $4.50 per share for a period of three years for aggregate gross proceeds of $550,000.

	During April to June 2013, the Company issued a total of 262,229 shares of Common Stock in respect of conversion of Series C Preferred Stock.	In April 2011, in connection with a consultancy agreement, the Company issued 120,000 shares of common stock (valued at $360,000) to Jerrald Ginder. On June 25, 2011, pursuant to an amendment to this consultancy agreement, the Company issued an additional 17,778 shares of common stock to Mr. Ginder in lieu of aggregate monthly cash payments due under the agreement totaling $60,000.

		In May 2011, the Company issued 57,779 shares of common stock together with Warrants to purchase 28,889 shares of Company common stock at an exercise price of $4.50 per share for a period of three years for aggregate gross proceeds of $195,000.

		On June 7, 2011, the Company completed the sale of 31.4 Units comprising Series C Convertible Preferred Shares and Warrants (the "Units") to accredited investors (the "Investors") (the "Preferred Offering") for aggregate proceeds of $1,570,000. The Units were issued pursuant to separate Series C Convertible Preferred Stock Purchase Agreements (the "Agreements") between the Company and each of the Investors. This sale was an initial closing (the "Initial Closing") under the Agreements which allows for maximum proceeds of $3,000,000. Each Unit was priced at $50,000 and comprised one share of Series C Preferred Convertible Stock convertible (at the Holder's option or mandatorily upon the occurrence of certain events) into 14,815 shares of the Company's Common Stock ($3.38 per share) and a Warrant to purchase 7,408 shares of the Company's Common Stock at $4.50 per share (subject to adjustments) for a period of three years (the "Warrant" or "Warrants"). A total of 31.4 shares of Series C Convertible Preferred Stock convertible into 465,186 shares of the Company's Common Stock and Warrants to purchase 232,593 shares of the Company's Common Stock were issued. On June 28, 2011, the Company completed a second closing of the Preferred Offering (the "Second Closing") with the sale of an additional 15.40 Units to Investors for aggregate proceeds of $770,000. An additional 15.40 shares of Series C Convertible Preferred Stock convertible into 228,149 shares of the common stock and Warrants to purchase 114,074 shares of the Company's common stock were issued in connection with the Second Closing. The Company entered into a Registration Rights Agreement with the Investors with respect to the Warrants. In December 2011, by mutual consent for technical reasons, the sale of 1 unit of Series C Convertible Preferred Stock convertible into 14,815 shares of the Company's Common Stock was rescinded; the Company returned the $50,000 invested and the investor returned the preferred share and the warrants to purchase 7,408 shares of the Company's Common Stock.

		On June 3, 2011, in connection with a consultancy agreement, the Company issued 103,334 shares of common stock (valued at $348,750) to GreenBridge Capital Partners IV, LLC. 68,889 of these shares remained held in escrow and are subject to clawback options, at the Company's sole descretion, exerciseable in equal tranches by April 15 and 30, 2012.

		On June 6, 2011, in connection with a consultancy agreement, the Company issued 6,667 shares of common stock (valued at $22,500) to Burnham Hill Advisors, LLC.

		Burnham Hill Partners LLC ("BHP") served as placement agent in connection with the sale of 24.8 Units in the Preferred Offering. Pursuant to a placement agent agreement with BHP, the Company paid BHP a cash placement fee equal to seven percent (7%) of the gross proceeds received by the Company from Units placed by BHP. Also pursuant to the placement agent agreement, the Company issued BHP Warrants (the "Placement Agent Warrants") to purchase a number of shares equal to seven percent (7%) of the number of shares of common stock issuable upon conversion of the 24.8 Units placed by BHP (25,719 shares) in the Preferred Offering. The Placement Agent Warrants are exercisable for three years from the date of issuance at an exercise price of $3.38 per share. In connection with the investor rescinding in December 2011 referred to above, the number of warrants was reduced to 24,682.

		On June 30, 2011, the entire principal and unpaid interest on a Debenture dated December 3, 2010 payable to Berardino Investment Group in the original principal amount of $40,000 was converted into 14,453 shares of common stock at a conversion price of $2.85 per share.

		Under the terms of a Consulting Agreement dated February 10, 2010 with Fountainhead, the Company was required to issue to Fountainhead fully vested warrants to purchase 260,425 shares of the Company's common stock should certain conditions be met during the term of the Consulting Agreement. These warrants are exercisable at $1.88 per share for a period of five years from February 2010. These warrants became issuable upon completion of the Preferred Offering and were issued in June 2011.

		In July 2011 the Company issued Warrants to purchase 15,334 shares of Company common stock at an exercise price of $4.50 per share for a period of three years to Millenium Capital Corporation in respect of consulting and advisory services.

		On August 4, 2011, the Company completed a final closing of the Preferred Offering (the "Final Closing") with the sale of an additional 13.2 Units to Investors for aggregate proceeds of $660,000. An additional 13.2 shares of Series C Convertible Preferred Stock convertible into 195,556 shares of the Company's Common Stock and Warrants to purchase 97,778 shares of the Company's Common Stock were issued in connection with the Final Closing. An aggregate of 60 Units were sold to Investors in the First Closing, Second Closing and Final Closing of the Preferred Offering for total proceeds of $3,000,000. A total of 60 shares of Series C Convertible Preferred Stock, convertible into an aggregate of 888,889 shares of Common Stock, and Warrants to purchase 444,444 shares of the Company's Common Stock.

		In August 2011 2,858 shares of Common Stock (valued at $10,000) to McCombie Group, LLC in respect of consulting agreements.

		On August 26, 2011, the Company completed a new sale of 3.8 Units comprising Series C Convertible Preferred Shares and Warrants (the "Units") to an accredited investor (the "Investor") (the " New Preferred Offering") for aggregate proceeds of $190,000. Each Unit was priced at $50,000 and comprised one share of Series C Preferred Convertible Stock convertible (at the Holder's option or mandatorily upon the occurrence of certain events) into 14,815 shares of the Company's Common Stock ($3.38 per share) and a Warrant to purchase 7,408 shares of the Company's Common Stock at $4.50 per share (subject to adjustments) for a period of three years (the "Warrant" or "Warrants").

		In September 2011 the Company entered into a Consulting Agreement with Dr Oscar Bronsther with regard to certain potential clinical studies utilizing Vycor's VBAS product. Under the terms of the agreement, Dr Bronsther received warrants to purchase up to 2,667 of the Company's Common Stock for a period of three years from September 30, 2011 at a price of $4.50 per share.

		On September 30, 2011 the Company issued 3,400 shares of Company common stock to Joe Simone in respect of an amendment to a previously disclosed consulting agreement.

		In December 2011 the Company issued 2,687 shares of Common Stock to Fountainhead Capital Partners Limited in respect of the exercise of December 2006 warrants, and received $443.26 in cash.

		On January 4, 2012, an aggregate of 95,667 restricted shares of the Company were issued to Prof. Sahraie and the University of Aberdeen, relating to the acquisition of all of the shares of Sight Science, Ltd. (“Sight Science”) by NovaVision.

		During the period from January 1, 2012 through December 31, 2012, the Company issued 5,928 shares of Common Stock (valued at $20,000) to each of Steven Girgenti and Dr Oscar Bronsther in consideration for services provided to the Board of Directors, 3,704 shares of Common Stock (valued at $12,500) to each of Alvaro Pasual-Leone, Jason Barton and Jose Romano, and 2,778 shares of Common Stock (valued at $9,375) to Josef Zihl in respect of their roles as members of the NovaVision, Inc. Scientific Advisory Board.

		In April 2012 the Company issued 8,889 shares of Common Stock (valued at $30,000) to Brunella Jacs, LLC in respect of consultancy services provided the Company.

		In June 2012, following the exercise of the Company’s option to repurchase shares of Common Stock from Greenbridge Capital Partners, IV, LLC, a total of 68,889 shares were repurchased into Treasury Stock at $1,033.33.

		In August 2012, 137,778 shares of Common Stock previously issued to Mr. Jerrald Ginder under the terms of Consulting Agreement were returned to the Company in consideration of a full settlement of performance and amounts due under the Consulting Agreement; the shares were retired.

		During the period from January 1, 2012 through December 2012, the Company issued a total of 348,152 shares of Common Stock in respect of conversion of Series C Preferred Stock.

		During the period from May 1, 2012 through December 31 2012, the Company issued a total of 50,372 shares of Common Stock at $3.375 for a total consideration of $170,000 to four investors.

		On November 30, 2012 the Company made a charitable donation of 14,815 shares of Common Stock valued at $16,667 to The Fiducuary Foundation.

		On November 30, 2012 the Company entered into 12 month consulting agreements with Del Mar Consulting, Inc and Alex Partners, LLC to provide investor relations and investor awareness consultancy services. Under these agreements, Del Mar and Alex Partners received shares 140,000 and 93,334 Common Shares valued at $157,500 and $105,000 respectively.

ShareBased_Compensation

Share-Based Compensation	6 Months Ended									12 Months Ended
Share-Based Compensation	Jun. 30, 2013									Dec. 31, 2012
Share-Based Compensation [Abstract]
SHARE-BASED COMPENSATION	8. SHARE-BASED COMPENSATION									10. SHARE-BASED COMPENSATION

	Stock Option Plan									Stock Option Plan

	The Company adopted the Vycor Medical, Inc Employee, Director, and Consultant Stock Plan (the "Plan") as of February 13, 2008. The Plan provides for both incentive stock options and nonqualified stock options to be granted to employees, officers, consultants, independent contractors, directors and affiliates of the Company. The board of directors establishes the terms and conditions of all stock option grants, subject to the Plan and applicable provisions of the Internal Revenue Code. Incentive stock options must be granted at an exercise price not less than the fair market value of the common stock on the grant date. The options granted to participants owning more than 10% of the Company's outstanding voting stock must be granted at an exercise price not less than 110% of the fair market value of the common stock on the grant date. The options expire on the date determined by the board of directors, but may not extend mare than 10 years from the grant date, while incentive stock options granted to participants owning more than 10% of the Company's outstanding voting stock expire five years from the grant date. The vesting period for employees is generally over three years. The vesting Period for non-employees is determined based on the services being provided. The maximum number of shares of stock which may be delivered under the plan shall automatically increase by a number sufficient to cause the number of shares covered by the plan to equal 10% of the total number of shares of stock then outstanding on a fully diluted basis.									The Company adopted the Vycor Medical, Inc. Employee, Director, and Consultant Stock Plan (the “Plan”) as of February 13, 2008. The Plan provides for both incentive stock options and nonqualified stock options to be granted to employees, officers, consultants, independent contractors, directors and affiliates of the Company. The board of directors establishes the terms and conditions of all stock option grants, subject to the Plan and applicable provisions of the Internal Revenue Code. Incentive stock options must be granted at an exercise price not less than the fair market value of the common stock on the grant date. The options granted to participants owning more than 10% of the Company’s outstanding voting stock must be granted at an exercise price not less than 110% of the fair market value of the common stock on the grant date. The options expire on the date determined by the board of directors, but may not extend mare than 10 years from the grant date, while incentive stock options granted to participants owning more than 10% of the Company’s outstanding voting stock expire five years from the grant date. The vesting period for employees is generally over three years. The vesting Period for non-employees is determined based on the services being provided. The maximum number of shares of stock which may be delivered under the plan shall automatically increase by a number sufficient to cause the number of shares covered by the plan to equal 10% of the total number of shares of stock then outstanding on a fully diluted basis.

	Under ASC Topic 718, the Company estimates the fair value of option awards on the date of grant using an option pricing model. The grant date fair value is recognized over the option vesting period, the period during which an employee is required to provide service in exchange for the award. No compensation cost is recognized for equity instruments for which employees do not render the requisite service. Under these standards, compensation cost for employee cost for employee stock-based awards is based on the estimated grant-date fair value and recognized over the vesting period of the applicable award on a straight-line basis. No employee stock options were granted for the six month periods ended June 30, 2013 and 2012.									Under ASC Topic 718, the Company estimates the fair value of option awards on the date of grant using an option pricing model. The grant date fair value is recognized over the option vesting period, the period during which an employee is required to provide service in exchange for the award. No compensation cost is recognized for equity instruments for which employees do not render the requisite service. Under these standards, compensation cost for employee cost for employee stock-based awards is based on the estimated grant-date fair value and recognized over the vesting period of the applicable award on a straight-line basis. No employee stock options were granted for the years ended December 31, 2012 and 2011.

	Initial grants of options to purchase 500,000 shares were issued under the Plan on February 13, 2008 to each of Kenneth T. Coviello, the Company's then Chief Executive Officer and Heather N. Vinas, the Company's then President at an exercise price of $0.135 per share. The options vested 33-1/3% on each of the first, second, and third anniversary of the grant and expire February 12, 2018. Following Heather Vinas' resignation as President of the Company in May 2010, 166,667 unvested options were cancelled. These options have been fully expensed.									Initial grants of options to purchase 3,334 shares were issued under the Plan on February 13, 2008 to each of Kenneth T. Coviello, the Company’s Chief Executive Officer and Heather N. Vinas, the Company’s President at an exercise price of $20.25 per share. The options vested 33-1/3% on each of the first, second, and third anniversary of the grant and expire February 12, 2018. Following Heather Vinas’ resignation as President of the Company in May 2010, 667 unvested options were cancelled. For the years ended December 31, 2012 and 2011, the Company recognized share-based compensation of $0 and $0, respectively.

	Stock appreciation rights may be granted either on a stand alone-basis or in conjunction with all or part of any other stock options granted under the plan. As of June 30, 2013 there were no awards of any stock appreciation rights.									Stock appreciation rights may be granted either on a stand alone basis or in conjunction with all or part of any other stock options granted under the plan. As of December 31, 2012 there were no awards of any stock appreciation rights.

	The Company from time to time issues common stock, stock options or common stock warrants to acquire services or goods from non-employees. Common stock, stock options and common stock warrants issued to other than employees or directors are recorded on the basis of their fair value, which is measured as of the "measurement date" using an option pricing model. The "measurement date" for options and warrants related to contracts that have substantial disincentives to non-performance is the date of the contract, and for all other contracts is the vesting date. Expense related to the options and warrants is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant.									The Company from time to time issues common stock, stock options or common stock warrants to acquire services or goods from non-employees. Common stock, stock options and common stock warrants issued to other than employees or directors are recorded on the basis of their fair value, which is measured as of the “measurement date” using an option pricing model. The “measurement date” for options and warrants related to contracts that have substantial disincentives to non-performance is the date of the contract, and for all other contracts is the vesting date. Expense related to the options and warrants is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant.

	The details of the outstanding rights, options and warrants and value of such rights, options and warrants are as follows:									The details of the outstanding rights, options and warrants and value of such rights, options and warrants are as follows:

										STOCK WARRANTS:		Number of shares				Weighted average exercise price
										STOCK WARRANTS:		Number of shares				per share
		STOCK WARRANTS:		Number of shares				Weighted average exercise price		Outstanding at December 31, 2010			777,371			$	2.35
		STOCK WARRANTS:		Number of shares				per share		Granted			987,869				3.78
		Outstanding at December 31, 2011		1,747,341			$	3.07		Exercised			(2,687	)			0.17
		Granted		4,667				4.5		Cancelled or expired			(15,212	)			12.96
		Exercised		-				-		Outstanding at December 31, 2011			1,747,341			$	3.07
		Cancelled or expired		(2,140	)			36		Granted			4,667				4.5
		Outstanding at December 31, 2012		1,749,874			$	3.03		Exercised			-				-
		Granted		-				-		Cancelled or expired			(2,140	)			36
		Exercised		(326,752	)		$	1.47		Outstanding at December 31, 2012			1,749,868			$	3.03
		Cancelled or expired		-				-
		Outstanding at June 30, 2013		1,423,122			$	3.39

										STOCK OPTIONS:		Number of shares				Weighted average exercise price
										STOCK OPTIONS:		Number of shares				per share
										Outstanding at December 31, 2010			5,557			$	20.25
		STOCK OPTIONS:		Number of shares				Weighted average exercise price		Granted			-				-
		STOCK OPTIONS:		Number of shares				per share		Exercised			-				-
		Outstanding at December 31, 2011		5,557			$	20.25		Cancelled or expired			-				-
		Granted		-				-		Outstanding at December 31, 2011			5,557			$	20.25
		Exercised		-				-		Granted			-				-
		Cancelled or expired		-				-		Exercised			-				-
		Outstanding at December 31, 2012		5,557			$	20.25		Cancelled or expired			-				-
		Granted		-				-		Outstanding at December 31, 2012			5,557			$	20.25
		Exercised		-				-
		Cancelled or expired		-				-		As of December 31, 2012, the weighted-average remaining contractual life of outstanding warrants and options is 1.93 and 5.12 years, respectively.
		Outstanding at June 30, 2013		5,557			$	20.25
										Non-Employee Stock Compensation
	As of June 30, 2013, the weighted-average remaining contractual life of outstanding warrants and options is 1.41 and 4.63 years, respectively.
										Under the terms of a consulting agreement dated February 2010, the Company issued fully vested warrants to Fountainhead to purchase up to 260,425 shares of the Company's common stock at $1.88 per share. The warrants are valid from February 10, 2010 for a period of five years. The fair value of these warrants was estimated using the Black-Scholes option pricing model and was amortized over the two-year life of the consultancy agreement, to February 2012. For year the ended December 31, 2012, $20,397 was recognized as share-based compensation in connection with this agreement.
	Non-Employee Stock Compensation
										During the year ended December 31, 2012, the Company issued an aggregate of 5,928 shares of common stock, valued at $20,000, to each of Steven Girgenti and Oscar Bronsther for services rendered to the board of directors. For the ended December 31, 2012, 2012, a total of $30,000 was recognized as share-based compensation for the issuance of these shares.
	During the six months ended June 30, 2013, the Company issued an aggregate of 4,114, 4,787 and 1,078 shares of common stock, respectively, valued at $10,000, $10,000 and $2,500 to each of Steven Girgenti, Oscar Bronsther and Lowell Rush for services rendered to the board of directors. For the six months ended June 30, 2013, a total of $22,500 was recognized as share-based compensation for the issuance of these shares.
										During the year ended December 31, 2012 the Company issued an aggregate of 3,704 shares of common stock, valued at $12,500, to each of Alvaro Pascual-Leone, Jason Barton and Jose Romano and 2,778 shares of Common Stock, valued at $9,375, to Josef Zihl for services rendered to the Scientific Advisory Board of NovaVision. For the ended December 31, 2012, an aggregate of $46,875 was recognized as share-based compensation for the issuance of these shares.
	During the six months ended June 30, 2013 the Company issued an aggregate of 1,594, 2,319 and 2,319 shares of common stock, respectively, valued at $4,688, to each of Alvaro Pascual-Leone, Jason Barton and Jose Romano and 2,261 shares of common stock valued at $6,250 to Josef Zihl for services rendered to the Scientific Advisory Board of NovaVision. For the six months ended June 30, 2013, an aggregate of $20,312 was recognized as share-based compensation for the issuance of these shares.
										Under the terms of a one-year consultancy agreement with Mr. Jerrald Ginder dated March 2011, as amended June 2011, the company issued an aggregate of 137,778 restricted shares of common stock of the Company. The stock was valued by the Company at $420,000 and was amortized over the life of the agreement as share-based compensation expense. For the year ended December 31, 2012, aggregate compensation recognized in respect of the Consulting Agreement, as amended, was $109,570. The consultancy was fully expensed as of March 31, 2012. This Agreement is further discussed in Note 14.
	On November 30, 2012 the Company entered into 12 month consulting agreements with Del Mar Consulting, Inc and Alex Partners, LLC to provide investor relations and investor awareness consultancy services. Under these agreements, Del Mar and Alex Partners received shares Common Shares valued at $157,500 and $105,000 respectively. The value of these shares is being amortized over the period of the agreement, and for the six months ended June 30, 2013 stock compensation of $131,250 was recognized as share-based compensation in connection with these agreements.
										In June 2011, the Company entered into a one-year Consulting Agreement with GreenBridge Capital Partners, IV, LLC, to provide consulting and advisory services to the Company. Under the terms of this agreement, GreenBridge was to receive up to 103,334 shares of the Company’s common stock. The stock was valued by the Company at $348,750 and was amortized over the life of the agreement as share-based compensation expense, in accordance with the performance under that agreement. As further discussed in Note 14, in May 2012 the Company exercised its option to repurchase 68,889 shares. Accordingly, a total of $116,250 was recognised as expense under this agreement. As at December 31, 2011, $113,344 had been recognized and for the year ended December 31, 2012, $2,906 was recognized as share-based compensation in connection with this agreement.
	Aggregate stock-based compensation expense charged to operations for stock and warrants granted to the above non-employees for the six months ended June 30, 2013 was $174,063. As of June 30, 2013, there was $107,375 of total unrecognized compensation costs related to warrant and stock awards and non-vested options.
										In April 2012 the Company entered into a consultancy agreement with Brunella Jacs, LLC for certain corporate and strategic advisory services. Under the terms of the agreement, Brunella Jacs was issued 8,889 shares of Common Stock, valued at $30,000. For the year ended December 31, 2012, aggregate compensation recognized in respect of this agreement was $30,000.
	Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing private placement purchase price. Expected volatility was based on the historical volatility of a peer group of publicly traded companies. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Constant Maturity rate.
										On May 14, 2012, the Company entered into a three-month Consulting Agreement with OneSource Advisors, LLC to provide consulting and advisory services to the Company, which was amended on August 31, 2012. Under the terms of the Consulting Agreement, on September 30, 2012 OneSource received warrants to purchase up to 4,667 of the Company’s Common Stock for a period of three years from May 14, 2012 at a price of $4.50 per share. The fair value of these warrants was estimated at $8,708 using the Black-Scholes model and the full value was recognized immediately.
	The following assumptions were used in calculations of the Black-Scholes option pricing model for options and warrants expensed in the three months ended June 30, 2013 and 2012:
										On November 30, 2012 the Company entered into 12 month consulting agreements with Del Mar Consulting, Inc and Alex Partners, LLC to provide investor relations and investor awareness consultancy services. Under these agreements, Del Mar and Alex Partners received shares Common Shares valued at $157,500 and $105,000 respectively. The value of these shares is being amortized over the period of the agreement, and for the year ended December 31, 2012 stock compensation of $21,875 was recognized as share-based compensation in connection with this agreements.

										Aggregate stock-based compensation expense charged to operations on stock and warrants granted to the above non-employees the year ended December 31, 2012 is $280,331. As of December 31, 2012, there was $240,625 of total unrecognized compensation costs related to warrant and stock awards and non-vested options.

			Six months ended June 30,						Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing private placement purchase price. Expected volatility was based on the historical volatility of a peer group of publicly traded companies. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Constant Maturity rate.
			2013			2012
	Risk-free interest rates		-			2.39%			The following assumptions were used in calculations of the Black-Scholes option pricing model in years ended December 31, 2012 and 2011:
	Expected life		-			3 years
	Expected dividends		-			0%					Year ended December 31,
	Expected volatility		-			96%					2012				2011
	Vycor Common Stock fair value		-			$1.88-$3.38			Risk-free interest rates			0.31-2.39	%			0.42-1.60	%
									Expected life		3 years				3 years
									Expected dividends			0	%			0	%
									Expected volatility			96-99	%			96-99	%
									Vycor Common Stock fair value		$	1.88-$4.50			$	3.00-$4.50

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2012
Income Taxes [Abstract]
INCOME TAXES	12. INCOME TAXES

	Loss Before Taxes

		December 31,			December 31,
		2012			2011
	Domestic	$	2,613,733		$	4,455,038
	Foreign		312,477			323,505
		$	2,926,210		$	4,778,543

	Deferred Income Taxes

	The Company has incurred net operating losses since inception. The Company has not reflected any tax benefit related to such net operating losses in the financial statements. Prior to August 15, 2007 the Company was a limited liability company and losses were passed through to the individual members, therefore the Company only has potential tax benefits from the date it became a ‘C’ corporation.

	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company and its subsidiaries’ deferred tax assets at December 31, 2012 and December 31, 2011 are as follows:

		December 31,			December 31,
		2012			2011
	Operating loss carry-forward	$	2,700,000		$	2,100,000
	Deferred tax asset before Valuation allowance		2,700,000			2,100,000
	Valuation allowance		(2,700,000	)		(2,100,000	)
	Net deferred tax asset	$	—		$	—

	In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income.

	The authoritative guidance requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Based on the level of historical taxable losses and projections of future taxable income (losses) over the periods in which the deferred tax assets can be realized, management currently believes that it is more likely than not that the Company will not realize the benefits of these deductible differences. Accordingly, management has determined that a 100% valuation allowance is appropriate at December 31, 2012 and December 31, 2011.

	Net Operating Loss Carry-Forwards

	As of December 31, 2012 and 2011, the Company has U.S. accumulated losses for tax purposes of approximately $7,600,000 and $6,000,000 respectively, which may be carried forward and offset against U.S. taxable income, and which expire during the tax years 2027 through 2031.

	Federal tax laws impose significant restrictions on the utilization of net operating loss carry-forwards and in the event of a change in ownership of the Company, as defined by the Internal Revenue Code Section 382. The Company’s net operating loss carry-forwards may be subject to the above limitations.

	As of December 31, 2012 and 2011, had German accumulated losses for tax purposes of approximately $490,000 and $450,000 respectively, which may be carried forward and offset against German taxable income subject to certain restrictions and limitations. Such carry-forwards are subject to certain restrictions and limitations in the event of changes in the NovaVision GmbH’s ownership.

	As of December 31, 2012 and 2011, had UK accumulated losses for tax purposes of approximately $100,000 and $0 respectively, which may be carried forward and offset against UK taxable income subject to certain restrictions and limitations.

	Tax Rates

	The applicable US income tax rate for the Company for both of the years ended December 31, 2012 and 2011 was 35%.

	Non-US subsidiaries are taxed according to the tax laws in their respective country of residence. The German applicable rate for both of the years ended December 31, 2012 and 2011 was 35%; the UK applicable rate for the year ended December 31, 2012 was 24% respectively.

	US income taxes and foreign withholding taxes were not provided for on undistributed earnings of the Company’s foreign subsidiaries. The Company intends to reinvest these earnings indefinitely in its foreign subsidiaries. If these earnings were distributed to US in the form of dividends or otherwise, after the repayment of intercompany debt, the Company would be subject to additional US income taxes (subject to an adjustment for foreign tax credits) and foreign withholding taxes.

	Uncertain Tax Position

	The Company has recorded no liability for income taxes associated with unrecognized tax benefits at the date of adoption and has not recorded any liability associated with unrecognized tax benefits during 2012 and 2011. Accordingly, the Company has not recorded any interest or penalty in regard to any unrecognized benefit.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended	12 Months Ended
Commitments and Contingencies	Jun. 30, 2013	Dec. 31, 2012
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	9. COMMITMENTS AND CONTINGENCIES	13. COMMITMENTS AND CONTINGENCIES

	Lease	Lease

	The Company leases approximately 10,000 sq. ft located at 6401 Congress Ave., Suite 140, Boca Raton, FL 33487 from Catexor Limited Partnership for a gross rent of $14,260 plus sales tax per month. The term of the lease is 5 years and 6 months terminating July, 2017. The Company's subsidiaries in Germany and the UK occupy properties on short term lease agreements. Rent expense for the six months ended June 30, 2013 and 2012 were $96,444 and $96,367 respectively.	The Company leases approximately 10,000 sq. ft. located at 6401 Congress Ave., Suite 140, Boca Raton, FL 33487 from Catexor Limited Partnership for a gross rent of $14,260 plus sales tax per month. The term of the lease is 5 years and 6 months terminating July, 2017. The Company’s subsidiaries in Germany and the UK occupy properties on short term lease agreements. Rent expense for the years ended December 31, 2012 and 2011 were $190,023 and $180,255, respectively.

	Potential German tax liability and connected professional fees	Potential German tax liability and connected professional fees

	In June 2012 the Company's German subsidiary received a preliminary assessment for Magdeburg City trade tax of approximately €75,000 (approximately $94,000). This assessment is for the 2010 fiscal year and relates to the Company's acquisition of the assets of the former NovaVision, Inc. An initial assessment for corporate tax for the same period has been preliminarily reduced to zero. The Company has not accepted this trade tax assessment and is in discussion with the relevant tax authorities with a view to its reduction. To the extent that this assessment, a higher or a reduced amount, is ultimately confirmed by the tax authorities, the Company believes it has a very strong claim against certain professional advisors which would offset the liability in full. Accordingly, the Company has made no provision for this liability for the six months ending June 30, 2013 or the year ended December 31, 2012.	In June 2012 the Company's German subsidiary received a preliminary assessment for Magdeburg City trade tax of approximately €75,000 (approximately $94,000). This assessment is for the 2010 fiscal year and relates to the Company's acquisition of the assets of the former NovaVision, Inc. An initial assessment for corporate tax for the same period has been preliminarily reduced to zero. The Company has not accepted this trade tax assessment and is in discussion with the relevant tax authorities with a view to its reduction. To the extent that this assessment, a higher or a reduced amount, is ultimately confirmed by the tax authorities, the Company believes it has a very strong claim against certain professional advisors which would offset the liability in full. Accordingly, the Company has made no provision for this liability for the period ended December, 2012.

	Related to the above tax situation, the Company has incurred advisory fees. The Company believes it also has a strong claim against certain professional advisors for a recovery of the full amount of the fees, however such recovery may be limited to a statutory minimum. Accordingly the Company has made a provision in the period ended December 31, 2012 for the full amount of these fees, being approximately €39,000 ($50,105); there were no costs incurred in the six months ending June 30, 2013.	Related to the above tax situation, the Company has incurred advisory fees. The Company believes it also has a strong claim against certain professional advisors for a recovery of the full amount of the fees, however such recovery may be limited to a statutory minimum. Accordingly the Company has made a provision in the period ended December 31, 2012 for the full amount of these fees, being approximately €39,000 ($50,105).

	Potential Patent Infringement	Potential Patent Infringement

	The Company was made aware in 2012 that a competitor had been granted a patent, which infringed that already issued to Vycor. Following investigation, the Company has taken steps to initiate an invalidation of that patent and enforce its patent rights. As with all patent infringement actions, there is some risk that the accused infringer will not be found to infringe the claims, and an additional risk that the accused infringer will successfully challenge the validity of the asserted claims.	The Company is aware that potential competitors are developing products similar to VBAS for sale in foreign markets. If those products come to market, Vycor has the option to take action to enforce its patent rights. As with all patent infringement actions, there is some risk that the accused infringer will not be found to infringe the claims, and an additional risk that the accused infringer will successfully challenge the validity of the asserted claims.

	VBAS Limited Product Recall	VBAS Limited Product Recall

	In August 2012 the Company initiated a limited product recall having identified a microscopic fiber in a single lot of its TC171105 model. Further investigation concluded that there was a very low incidence of this microscopic fiber in the lot, which had not been picked up during the manufacturer's inspection process. The FDA was notified and all customers with units that had been distributed (a total of 5 customers in the U.S. and 2 customers internationally) were contacted and the units were recalled and replaced with re-inspected and passed units, or internationally re-inspected under 100% enhanced inspection guidelines; this recall and replacement process was completed in the US in September 2012 and internationally in November 2012 and there are no affected units on the marketplace. In January 2013, following their review, FDA classified the recall as a Class I and terminated the recall in May 2013.	In August 2012 the Company initiated a limited product recall having identified a microscopic fiber in a single lot of its TC171105 model. Further investigation concluded that there was a very low incidence of this microscopic fiber in the lot, which had not been picked up during the inspection process. The FDA was notified and all customers with units that had been distributed (a total of 5 customers in the U.S. and 2 customers internationally) were contacted and the units were recalled and replaced with re-inspected and passed units, or internationally re-inspected under 100% enhanced inspection guidelines; this recall and replacement process was completed in November 2012 and there are no affected units on the marketplace. In January 2013, following their review, classified the recall as a Class I. The Company is in the process of closing out this recall with the FDA.

	Vycor re-inspected all remaining units in the lot prior to shipment under 100% enhanced inspection procedures and took steps to ensure that this issue was contained to this lot and that other lots and products were not affected (this is one of 12 products sold by Vycor). The likely source of the fiber was identified and corrective steps implemented in both the manufacturing and inspection processes to ensure that the issue would not re-occur.	Vycor re-inspected all remaining units in the lot prior to shipment under 100% enhanced inspection procedures and took steps to ensure that this issue was contained to this lot and that other lots and products were not affected (this is one of 12 products sold by Vycor). The likely source of the fiber was identified and corrective steps implemented in both the manufacturing and inspection processes to ensure that the issue would not re-occur.

	Management believes that a decline in sales during February 2013 may have at least partially been the result of the posting by the FDA in late January 2013 of the Class 1 classification to the recall and which created some short-term market instability.	Vycor is not able at this time to determine whether there will be any financial impact on the Company as a result of this recall. However, the limited replacement of defective units is immaterial and at this time the Company does not believe there are additional costs of sufficient materiality to make a reserve provision in its financial statements. Vycor’s customers have appreciated that Vycor took swift voluntary action to remove this product from the marketplace, even though the incidence of this fiber and therefore the risk was low, before any units could be used, and to maintain Vycor’s high safety and quality standards.



	Notwithstanding, for the period commencing March 1, 2013 and continuing through June 30, 2013, Vycor Medical's sales have returned to pre-February 2013 levels and Vycor is not able at this time to determine whether there will be any additional financial impact on the Company as a result of this recall. Vycor's customers have appreciated that Vycor took swift voluntary action to remove this product from the marketplace, even though the incidence of this fiber and therefore the risk was low, before any units could be used, and to maintain Vycor's high safety and quality standards.

Consulting_and_Other_Agreement

Consulting and Other Agreements	6 Months Ended	12 Months Ended
Consulting and Other Agreements	Jun. 30, 2013	Dec. 31, 2012
Consulting and Other Agreements [Abstract]
CONSULTING AND OTHER AGREEMENTS	10. CONSULTING AND OTHER AGREEMENTS
		14. CONSULTING AND OTHER AGREEMENTS
	The Company has entered into no new consulting or other agreements during the six months ended June 30, 2013. The following agreements remained in force during the period:
		The Company has entered into the following consulting and other agreements during the year ended December 31, 2012:
	Consulting Agreement with Fountainhead Capital Management Limited ("Fountainhead")
		Consulting Agreement with OneSource Advisors, LLC.
	In February 2010 the Company entered into a Consulting Agreement with Fountainhead, which was the subject of a Supplement Agreement in May, 2011 to recognize Fountainhead's expanded responsibilities as a result of the acquisition by the Company of the assets of NovaVision, Inc. Under the terms of the Agreement and Supplement, the Company pays to Fountainhead a monthly retainer of $37,500 ($8,500 under the Original Agreement and $29,000 under the Supplement). This monthly retainer is accrued and paid out to Fountainhead at the option of Fountainhead as follows: (i) in Vycor stock or (ii) in cash following the closing of a fundraising of no less than $2.5 million or on the sale of the Company or a substantial part of the assets thereof at any time after June 30, 2011. Notwithstanding, Fountainhead has the option to receive up to $5,000 of monthly retainer in cash each month.
		On May 14, 2012, the Company entered into a three-month Consulting Agreement with OneSource Advisors, LLC to provide consulting and advisory services to the Company, which was amended on August 31, 2012. Under the terms of the Consulting Agreement, on September 30, 2012 OneSource received warrants to purchase up to 4,667 of the Company’s Common Stock for a period of three years from May 14, 2012 at a price of $4.50 per share.
	Consulting Agreement with Del Mar Consulting Group, Inc and Alex Partners, LLC.
		Consulting Agreement with Del Mar Consulting Group, Inc and Alex Partners, LLC.
	On November 30, 2012 the Company entered into 12 month consulting agreements with Del Mar Consulting, Inc and Alex Partners, LLC to provide investor relations and investor awareness consultancy services. Under these agreements, Del Mar and Alex Partners received Common Shares valued at $157,500 and $105,000 respectively and cash of $7,200 and $4,800 respectively. Del Mar and Alex Partners have agreed to take Vycor Common Stock in lieu of cash payments for July and August, 2013.
		On November 30, 2012 the Company entered into 12 month consulting agreements with Del Mar Consulting, Inc and Alex Partners, LLC to provide investor relations and investor awareness consultancy services. Under these agreements, Del Mar and Alex Partners received shares Common Shares valued at $157,500 and $105,000 respectively.

		The following agreements remained in force during the period:

		Consulting Agreement with Fountainhead Capital Management Limited ("Fountainhead")

		In February 2010 the Company entered into a Consulting Agreement with Fountainhead, which was the subject of a Supplement Agreement in May, 2011 to recognize Fountainhead's expanded responsibilities as a result of the acquisition by the Company of the assets of NovaVision, Inc. Under the terms of the Agreement and Supplement, the Company will pay to Fountainhead a monthly retainer of $37,500 ($8,500 under the Original Agreement and $29,000 under the Supplement). This monthly retainer shall be accrued and paid out to Fountainhead at the option of Fountainhead as follows: (i) in Vycor stock at any time at $1.88 per share for the Original Agreement and $3.38 per share for the Supplement; or (ii) in cash following the closing of a fundraising of no less than $2.5 million or on the sale of the Company or a substantial part of the assets thereof at any time after June 30, 2011. Notwithstanding, Fountainhead has the option to receive up to $5,000 of monthly retainer in cash each month, commencing April 1, 2011. The term of the Consulting Agreement is to May 5, 2013.

		Consulting Agreement with Jerrald Ginder

		In March 2011, as amended June 2011, the Company entered into a one-year consultancy agreement with Mr. Jerrald Ginder, a sales executive of Stryker Corporation, effective April 1, 2011. Under the terms of the agreement Mr. Ginder received 137,778 restricted shares of common stock of the Company. The stock was valued by the Company at $420,000 and was amortized over the life of the agreement ending March 30, 2012 as share-based compensation expense.

		On August 7, 2012, the Company and Mr. Ginder reached a Settlement and Mutual General Release Agreement relative to the Consulting Agreement whereby it was acknowledged by all parties that the Consulting Agreement expired as of April 1, 2012 and that Mr. Ginder would cause to be delivered to the Company 137,778 shares of Company Common Stock previously issued to Mr. Ginder in consideration of a full settlement of performance and amounts due under the Consulting Agreement and a mutual general release among the parties. As of September 12, 2012, these shares were returned to the Company and retired.

		Consulting Agreement with GreenBridge Capital Partners, IV, LLC

		On June 3, 2011, the Company entered into a Consulting Agreement ("Consulting Agreement") with GreenBridge Capital Partners, IV, LLC, a Delaware limited liability company ("GreenBridge"), to provide consulting and advisory services to the Company. Under the terms of this agreement GreenBridge was to receive up to 103,334 shares of the Company's Common Stock. Said shares were subject to a Company repurchase option, which could be exercised within specified time periods at the Company's sole discretion.

		As of June 30, 2012, the Company had exercised its option to repurchase 68,889 of the 103,334 shares for a total purchase price of $1,033.33. The Company also believes that it is entitled to the return of the remaining 34,445 shares because it contends that GreenBridge breached the Consulting Agreement and failed to deliver the services it was obligated to perform pursuant to the terms of the Consulting Agreement. The Company has filed an action relative to this matter with the American Arbitration Association alleging causes of action based upon breach of contract and fraud. In March 2013 Greenbridge returned to the Company all of the 34,445 shares being sought by the Company. At this time, the Company cannot project whether it will achieve a successful result in connection with the remainder of the action or any other related actions. The Company has reserved its right to claim legal costs.

		Agreement with Partizipant, LLC

		On July 31, 2011, the Company entered into an Agreement (the "Agreement") with Partizipant, LLC, a Delaware limited liability company ("Partizipant"), to provide a broad range of investor relations and public relations services. Pursuant to the Agreement, the Company agreed to pay Partizipant a one-time payment of $300,000.

		The Company believes that Partizipant has not adequately performed its services under the Agreement and that it is entitled to the return of a substantial portion of the amounts paid under the terms of the Agreement. The Company has filed an action relative to this matter with the American Arbitration Association alleging causes of action based upon breach of contract and fraud. This action is still in its early stages and a hearing is set for September 2013. At this time, the Company cannot project whether it will achieve a successful result in this action.

Related_Party_Transactions

Related Party Transactions	6 Months Ended	12 Months Ended
Related Party Transactions	Jun. 30, 2013	Dec. 31, 2012
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	11. RELATED PARTY TRANSACTIONS	15. RELATED PARTY TRANSACTIONS

	During January to June 2013, the Company issued unsecured, subordinated loan notes to: Fountainhead for a total of $234,225; and to Peter Zachariou, a director of the Company, for a total of $190,000. During July and August 2013, the Company issued unsecured, subordinated loan notes to Fountainhead for a total of $90,000. The loan notes are subordinated to the Company's secured debentures and Preferred C Stock of the Company, bear interest at a rate of 6% are due on demand or by their one-year anniversary.	During July to December 2012, the Company issued unsecured, subordinated loan notes to: Fountainhead for a total of $309,900; and to Peter Zachariou, a director of the Company, for a total of $115,550. The loan notes are subordinated to the Company’s secured debentures and Preferred C Stock of the Company, bear interest at a rate of 6% are due on demand or by their one-year anniversary.

	In March 2013, Fountainhead and Peter Zachariou, a director of the Company, extended the maturity of secured loans totaling $1,016,362 and $300,000 respectively from March 31, 2013 to December 31, 2013.	In November 2012, Fountainhead and Peter Zachariou, a director of the Company, extended the maturity of secured loans totaling $1,016,362 and $300,000 respectively from December 31, 2012 to March 31, 2013. These have been subsequently extended to December 31, 2013.

	In April 2013, in connection with her departure from the Board of Directors, the Company and Heather Vinas entered into a Warrant Exercise and Share Sales Agreement (the "Agreement"). Under the terms of the Agreement Mrs. Vinas agreed to exercise her warrants to purchase 54,834 shares of Common Stock, which are exercisable on a cashless basis, at a price of $2.60 per share and receive 32,152 shares of Common Stock. Following this exercise, Mrs. Vinas holds an aggregate of 66,272 shares of Common Stock. The Agreement also requires Mrs. Vinas not to sell more than 16,000 shares in any 30-day period.	On November 30, 2012 the Company entered into an Option Agreement with Heather Vinas, a director of the Company, to purchase up to 54,834 warrants to purchase Common Stock held by Mrs Vinas at $0.87. On January 1, 2013 and on the first day of each calendar month thereafter, the Company shall have the right to an Option Exercise with respect to 4,570 Warrants. The Company, in its sole discretion, may elect to cease its Option Exercises at any time. This was subsequently amended on January 15, 2013 to commence on February 15, 2013. The Company and Mrs Vinas are currently in discussions regarding this agreement.

	During April and May 2013, Fountainhead Capital Management sold warrants to purchase 162,250 shares of Vycor Common Stock at an exercise price of $1.88 per share. These warrants were granted to Fountainhead by the Company in February 2010 and were sold by Fountainhead to investors at a price of $0.10 per warrant share. The warrants were immediately exercised by the investors.	There were no other related party transactions during the year ended December, 2012 other than the payment or accrual of fees under the Fountainhead Consulting agreement described in 14 above.

	There were no other related party transactions during the six months ended June 30, 2013 other than the payment or accrual of fees under the Fountainhead Consulting agreement described in 10 above.

Subsequent_Events

Subsequent Events	6 Months Ended	12 Months Ended
Subsequent Events	Jun. 30, 2013	Dec. 31, 2012
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS	16. SUBSEQUENT EVENTS

	The Company evaluated subsequent events through the date the financial statements were issued and filed with this Form 10Q.	Share Issuance

		During January 2013, the Company issued 1,482 shares of Common Stock (valued at $5,000) to each of Steven Girgenti and Oscar Bronsther, M.D. in consideration for services provided to the Board of Directors, and 926 shares of Common Stock (valued at $3,125) to each of Alvaro Pasual-Leone and Josef Zihl in respect of their roles as members of the NovaVision, Inc. Scientific Advisory Board.

	Share Issuance	Reverse Stock Split

	During July 2013, the Company issued 2,155 shares of Common Stock (valued at $5,000) to Steven Girgenti, in consideration for services provided to the Board of Directors; and 659 and 1,319 shares of Common Stock respectively (valued at $1,563 and $3,125 respectively) to Alvaro Pascual-Leone and Josef Zihl in respect of their roles as members of the NovaVision, Inc. Scientific Advisory Board.	On January 11, 2013, the Company filed a Certificate of Amendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split of 1 for 150 on the issued and outstanding Common Stock par value $0.0001 (“Common Stock”). On January 15, 2013 (the “Effective Date”), the Company effectuated its reverse stock split. On the Effective date, the Company implemented a one for 150 share reverse split of its Common Stock. On the Effective Date, the Company’s pre-split 892,749,897 shares of Common Stock became 5,951,744 post-split shares of Common Stock, including the issuance of 79 shares of Common Stock for the round-up of partial shares. In connection with the reverse split, the Company’s authorized capital was not changed. All relevant information relating to the number of shares and per share information has been retrospectively adjusted to reflect the recerse stock split for all periods presented.

	During July 2013, the Company issued 15,000 shares of Common Stock in respect of the Advisory Agreement described below.	Loan Funding

	During August 2013, Del Mar and Alex Partners were issued 7,200 and 4,800 shares of Common Stock, respectively, valued at $14,400 and $9,600, respectively, in lieu of cash consulting fees for the months of July and August 2013.	During January to March, the Company issued unsecured, subordinated loan notes to: Fountainhead for a total of $130,000; and to Peter Zachariou, a director of the Company, for a total of $145,000. The loan notes are subordinated to the Company’s secured debentures and Preferred C Stock of the Company, bear interest at a rate of 6% are due on demand or by their one-year anniversary.

	Conversion of Preferred Shares	Sight Science Acquisition Deferred Consideration Amendment

	During July 2013, the Company issued a total of 7,408 shares of Common Stock in respect of the conversion of Series C Preferred Stock.	In February 2013, The Company and its subsidiary, Nova Vision, Inc. agreed, among other things, to extend the payment schedule for the payment of the cash consideration and working capital excess by the Company to the University of

	Loan Funding	Aberdeen and Prof. Arash Sahriae pursuant to the original Sale Agreement between the parties dated as of January 2012 to a period ending June 30, 2013.

	During July and August, the Company issued unsecured, subordinated loan notes to: Fountainhead for a total of $90,000; and to Craig Kirsch for a total of $10,000. The loan notes are subordinated to the Company's secured debentures and Preferred C Stock of the Company, bear interest at a rate of 6% are due on demand or by their one-year anniversary.	GreenBridge Litigation

	Advisory and Placement Agent Agreements	In March 2013 Greenbridge returned to Vycor all of the 34,445 shares being sought by the Company. At this time, the Company cannot project whether it will achieve a successful result in connection with the remainder of the Action or any other related actions.

	On July 2, 2013, the Company entered into two agreements with a registered broker-dealer one to provide certain financial advisory services to the Company ("Advisory Agreement") and the other to act as placement agent for the Company ("Placement Agent Agreement").	Loan Extensions

	Under the terms of the Advisory Agreement, the broker-dealer is engaged on a non-exclusive basis to provide financial advisory services to the Company for at least ninety (90) days and thereafter until either party terminates the arrangement. Under the terms of the Advisory Agreement, the Company will issue 60,000 restricted shares of Company Common Stock to the broker-dealer, 15,000 of which are issuable on the date of the execution of the Agreement and 7,500 additional shares to be issued on a monthly basis commencing the 7^th month following execution of the Agreement until the 12^th month following execution of the Agreement. The Agreement also calls for the Company to reimburse certain out-of-pocket expenses.	In March 2013, Fountainhead and Peter Zachariou, a director of the Company, extended the maturity of secured loans totaling $1,016,362 and $300,000 respectively from March 31, 2013 to December 31, 2013.

	Under the terms of the Placement Agent Agreement, the Company engaged a broker-dealer as its exclusive placement agent until the later of (i) 90 days from the date of execution of the Agreement or (ii) the end of the offering period of any securities financing undertaken by the Company in connection with the Placement Agent Agreement. Normal placement agents fees and expense reimbursement will be payable. Any offering will be undertaken on a "best efforts" basis and the proceeds would be used for working capital and general corporate purposes.	Option Agreement

		On October 12, 2012 the Company entered into an Option Agreement with Kenneth T. Coviello, the Company’s former Chief Executive Officer, to purchase up to 109,668 warrants to purchase Common Stock held by Mr. Coviello at $0.87. On January 1, 2013 the Company shall have the right to an Option Exercise with respect to 27,417 Warrants. On the first day of each calendar month therafter, the Company shall have the right to an Option Exercise with respect to 9,139 Warrants per month, for a period of 9 months. On January 15, 2013 this was amended to commence on February 15, 2013. The Company, in its sole discretion, may elect to cease its Option Exercises at any time.

		On November 30, 2012 the Company entered into an Option Agreement with Heather Vinas, a director of the Company, to purchase up to 54,834 warrants to purchase Common Stock held by Mrs Vinas at $0.87. On January 1, 2013 and on the first day of each calendar month thereafter, the Company shall have the right to an Option Exercise with respect to 4,570 Warrants. On January 15, 2013 this was amended to commence on February 15, 2013. The Company, in its sole discretion, may elect to cease its Option Exercises at any time.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)

6 Months Ended

12 Months Ended

Jun. 30, 2013

Dec. 31, 2012

Significant Accounting Policies [Abstract]

Principles of Consolidation

Revenue Recognition

Deferred revenue results from patients paying for the therapy in advance of receiving the therapy.

Accounts Receivable and Allowance for Doubtful Accounts Receivable

Inventories

Property and equipment

Impairment of long lived assets

Research and Development

Software Development Costs

Uses of estimates in the preparation of financial statements

Stock Compensation

Convertible Instruments

We evaluate and account for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”.

Common Stock Purchase Warrants and Other Derivative Financial Instruments

Fair Value Measurements

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

Net Loss Per Share

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:

December 31,

June 30,

2012

2011

2013

2012

Stock options outstanding

5,557

Stock options outstanding

5,557

Warrants to purchase common stock

1,749,874

1,747,347

Warrants to purchase common stock

1,423,123

1,745,207

Debentures convertible into common stock

368,726

Debentures convertible into common stock

368,727

368,726

Preferred shares convertible into common stock

582,233

930,382

Preferred shares convertible into common stock

320,007

663,719

Total

2,706,390

3,052,012

Total

2,117,414

2,783,209

Recent Accounting Pronouncements

Business_Acquisition_Tables

Business Acquisition (Tables)	12 Months Ended
Business Acquisition (Tables)	Dec. 31, 2012
Business Acquisition [Abstract]
Purchase price allocation to estimated fair value of assets acquired and liabilities assumed
		Amount

	Trademarks and Tradenames	$	121,157
	Patents		180,183
	Internally Developed Software		363,472
	Other Net Assets		(758	)
			664,054
	Negative Goodwill on acquisition		(66,394	)
	Purchase Price	$	597,660

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	6 Months Ended				12 Months Ended
Significant Accounting Policies (Tables)	Jun. 30, 2013				Dec. 31, 2012
Significant Accounting Policies [Abstract]
Potential shares of common stock that are not included in the calculation of diluted net loss per share
						December 31,		December 31,
						2012		2011
			June 30,	June 30,	Stock options outstanding		5,557		5,557
			2013	2012	Warrants to purchase common stock		1,749,874		1,747,347
		Stock options outstanding	5,557	5,557	Debentures convertible into common stock		368,726		368,726
		Warrants to purchase common stock	1,423,123	1,745,207	Preferred shares convertible into common stock		582,233		930,382
		Debentures convertible into common stock	368,727	368,726	Total		2,706,390		3,052,012
		Preferred shares convertible into common stock	320,007	663,719
		Total	2,117,414	2,783,209

Notes_Payables_Tables

Notes Payables (Tables)	6 Months Ended						12 Months Ended
Notes Payables (Tables)	Jun. 30, 2013						Dec. 31, 2012
Notes Payable [Abstract]
Components of notes payable
				June 30,		December 31,		31-Dec-12		31-Dec-12
				2013		2012	On December 29, 2009 and February 3, 2010, the Company issued convertible debentures in the amount of $371,362 and $70,000, respectively, payable to Fountainhead Capital Management (“Fountainhead”), the beneficial owner of more than 50% of the Company’s common stock. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $1.88 per share, subject to adjustment and does not require bifurcation. These debentures were originally due August 31, 2010 and the due date has been extended over time to December 31, 2013.		441,362		441,362
		On December 29, 2009 and February 3, 2010, the Company issued convertible debentures in the amount of $371,362 and $70,000, respectively, payable to Fountainhead Capital Management ("Fountainhead"), the beneficial owner of more than 50% of the Company's common stock. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $1.88 per share, subject to adjustment and does not require bifurcation. These debentures were originally due August 31, 2010 and the due date has been extended over time to December 31, 2013		441,362		441,362
							On September 30, 2010 and October 14, 2010, the Company issued convertible debentures payable to Fountainhead in the amount of $85,000 and $90,000, respectively. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $2.63 per share, subject to adjustment and does not require bifurcation. The debentures were originally due August 31, 2011, and the due date has been extended over time to December 31, 2013.		175,000		175,000

							On October 26, 2010 and November 15, 2010, the Company issued debentures payable to Fountainhead in the amount of $77,500 and $322,500, respectively. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The debentures were originally due August 31, 2011, and the due date has been extended over time to December 31, 2013.		400,000		400,000

							On November 15, 2010, the Company issued a convertible debenture in the amount of $350,000 payable to Peter Zachariou, a Director of the Company. This debenture accrues interest rate of 6% per annum, is due on December 31, 2012, is secured by a first priority security interest in all of the assets of the Company, and is senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debenture then outstanding into shares of common stock of the Company at the conversion price of $2.85 per share, subject to adjustment and does not require bifurcation. On December 20, 2010, the Company repaid $50,000 of this debenture and removed the convertible rights. The debentures were originally due December 31, 2012 and the due date has been extended over time to December 31, 2013.		300,000		300,000

		On September 30, 2010 and October 14, 2010, the Company issued convertible debentures payable to Fountainhead in the amount of $85,000 and $90,000, respectively. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $2.63 per share, subject to adjustment and does not require bifurcation. The debentures were originally due August 31, 2011, and the due date has been extended over time to December 31, 2013.		175,000		175,000	On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011. In connection with the loan the Company also issued EuroAmerican warrants to purchase 2,667 shares of the Company’s common stock at an exercise price of $4.50 per share for a period of three (3) years. On June 25, 2011 the due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company at the conversion price of $4.50 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended over time to June 30th, 2013		300,000		300,000

		On October 26, 2010 and November 15, 2010, the Company issued debentures payable to Fountainhead in the amount of $77,500 and $322,500, respectively. These debentures accrue interest at a rate of 6% per annum, are secured by a first priority security interest in all of the assets of the Company, and are senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The debentures were originally due August 31, 2011, and the due date has been extended over time to December 31, 2013.		400,000		400,000	In the period July to December 2012 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $300,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		300,900		-

		On November 15, 2010, the Company issued a convertible debenture in the amount of $350,000 payable to Peter Zachariou, a Director of the Company. This debenture accrues interest rate of 6% per annum, is secured by a first priority security interest in all of the assets of the Company, and is senior to or pari passu with, all other obligations of the Company, subject to certain conditions. The Holder is entitled to convert all or any amount of the principal face amount of the debenture then outstanding into shares of common stock of the Company at the conversion price of $2.85 per share, subject to adjustment and does not require bifurcation. On December 20, 2010, the Company repaid $50,000 of this debenture and removed the convertible rights. The debentures were originally due December 31, 2012 and the due date has been extended over time to December 31, 2013.		300,000		300,000	In the period August to December 2012 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $115,500. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		115,500		-

		On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. ("EuroAmerican"). The term note bears interest at 16% per annum and was due June 25, 2011. In connection with the loan the Company also issued EuroAmerican warrants to purchase 400,000 shares of the Company's common stock at an exercise price of $4.50 per share for a period of three (3) years. On June 25, 2011 the due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company at the conversion price of $4.50 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended over time to September 30, 2013		300,000		300,000	In the period August to December 2012 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $98,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		98,550		-

		In the period July to December 2012 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $300,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		300,900		300,900	In September 2012 the Company issued short term, unsecured notes payable to Osbaldo Trading Limited in the amount of $42,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		42,900		-

		In the period August to December 2012 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $115,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		115,550		115,550	Unsecured, non-interest bearing loan from the chief executive of NovaVision AG, advanced a total of €8,250 to NovaVision AG, repayable in monthly installments. As of June 30, 2012 the loan had been repaid in full and December 31, 2011 the remaining balance was €8,250.		-		10,660

		In the period August to December 2012 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $98,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		98,550		98,550	Insurance policy finance agreements		21,290		9,103

							Total Notes Payable:	$	2,195,502	$	1,636,1


		In September 2012 the Company issued short term, unsecured notes payable to Osbaldo Trading Limited in the amount of $42,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		42,900		42,900

		In the period January to June 2013 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $234,225. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		234,225		-

		In the period January to June 2013 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $190,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company.		190,000		-

		Insurance policy finance agreements. During the six months ended June 30, 2013 the Company received proceeds from Insurance policy finance agreement of $18,737 and made repayments of $28,236		11,711		21,210

		Total Notes Payable:	$	2,610,198	$	2,195,502

Segment_Reporting_Geographical1

Segment Reporting, Geographical Information (Tables)	6 Months Ended										12 Months Ended
Segment Reporting, Geographical Information (Tables)	Jun. 30, 2013										Dec. 31, 2012
Segment Reporting, Geographical Information [Abstract]
Business segments information				Three Months Ended June 30,				Six Months Ended June 30,				December 31,
				2013		2012		2013		2012		2012		2011
		Revenue:									Revenue:
		Vycor Medical	$	146,358	$	138,239	$	277,024	$	460,021	Vycor Medical	$	770,676	$	548,463
		NovaVision		88,596		127,147		189,604		237,966	NovaVision		434,587		422,904
		Total Revenue	$	234,954	$	265,386	$	466,628	$	697,987	Total Revenue	$	1,205,263	$	971,367
		Gross Profit:									Gross Profit:
		Vycor Medical	$	135,152	$	118,206	$	251,431	$	378,795	Vycor Medical		668,729		439,422
		NovaVision		71,908		106,932		157,285		199,523	NovaVision		357,004		355,687
		Total Gross Profit	$	207,060	$	225,138	$	408,716	$	578,318	Total Gross Profit	$	1,025,733	$	795,109

												December 31,
												2012		2011
				June 30,		December 31,					Total Assets:
				2013		2012					Vycor Medical		1,055,026		2,068,084
		Total Assets:									NovaVision		1,506,134		1,503,556
		Vycor Medical	$	859,185	$	1,055,026					Total Assets		2,561,160	$	3,571,640
		NovaVision		1,340,896		1,506,134
		Total Assets	$	2,200,081	$	2,561,160
Summary of geographic information				Three Months Ended June 30,				Six Months Ended June 30,
				2013		2012		2013		2012		December 31,
		Revenue:										2012		2011
		United States	$	180,792	$	205,602	$	360,307	$	567,850	Revenue:
		Europe		54,162		59,784		106,321		130,137	United States	$	952,256	$	740,967
		Total Revenue	$	234,954	$	265,386	$	466,628	$	697,987	Europe		253,007		230,400
		Gross Profit:									Total Revenue	$	1,205,263	$	971,367
		United States	$	161,140	$	172,994	$	317,328	$	463,764	Gross Profit:
		Europe		45,920		52,144		91,388		114,554	United States	$	810,809	$	607,702
		Total Gross Profit	$	207,060	$	225,138	$	408,716	$	578,318	Europe		214,924		194,651
											Total Gross Profit	$	1,025,733	$	802,353
											Total Assets:
											United States	$	2,475,933	$	3,470,993
				June 30,		December 31,					Germany		85,227		100,647
				2013		2012					Total Assets		2,561,160	$	3,571,640
		Total Assets:
		United States	$	1,650,219	$	1,935,638
		Europe		549,862		625,523
		Total Assets	$	2,200,081	$	2,561,160

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
Property and Equipment (Tables)	Dec. 31, 2012
Property and Equipment [Abstract]
Summary of property and equipment and the estimated live
		Estimated Useful Lives	December 31,			December 31,
		Estimated Useful Lives	2012			2011

	Machinery and equipment	3 years		123,355		$	106,368
	Leasehold Improvements	5 years		6,206			-
	Purchased Software	3 years		17,833			15,607
	Molds and Tooling	5 years		234,230			234,230
	Furniture and fixtures	7 years		21,533			21,130
	Therapy Devices	3 years		76,513			59,065
	Internally Developed Software	5 years		923,215			559,304
				1,402,885			995,704

	Less: Accumulated depreciation and amortization			(575,496	)		(324,413	)

	Property and Equipment, net		$	827,389		$	671,291

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
Intangible Assets (Tables)	Dec. 31, 2012
Intangible Assets [Abstract]
Summary of Intangible Assets		December 31,
		2012			2011
	Amortized intangible assets: Patent (8 years useful life)
	Gross carrying Amount	$	705,662		$	492,147
	Accumulated Amortization		(202,767	)		(112,568	)
		$	502,895		$	379,579

	Amortized intangible assets: Website (5 years useful life)
	Gross carrying Amount	$	18,909		$	18,909
	Accumulated Amortization		(16,137	)		(14,003	)
		$	2,772		$	4,906

	Intangible assets not subject to amortization
	Trademarks		251,157			130,000

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	6 Months Ended							12 Months Ended
Share-Based Compensation (Tables)	Jun. 30, 2013							Dec. 31, 2012
Share-Based Compensation [Abstract]
Details of the outstanding rights, options and warrants and value of such rights, options and warrants
		STOCK WARRANTS:	Number of shares				Weighted average exercise price	STOCK WARRANTS:	Number of shares			Weighted average exercise price
		STOCK WARRANTS:	Number of shares				per share	STOCK WARRANTS:	Number of shares			per share
		Outstanding at December 31, 2011	1,747,341			$	3.07	Outstanding at December 31, 2010		777,371		$	2.35
		Granted	4,667				4.5	Granted		987,869			3.78
		Exercised	-				-	Exercised		(2,687	)		0.17
		Cancelled or expired	(2,140	)			36	Cancelled or expired		(15,212	)		12.96
		Outstanding at December 31, 2012	1,749,874			$	3.03	Outstanding at December 31, 2011		1,747,341		$	3.07
		Granted	-				-	Granted		4,667			4.5
		Exercised	(326,752	)		$	1.47	Exercised		-			-
		Cancelled or expired	-				-	Cancelled or expired		(2,140	)		36
		Outstanding at June 30, 2013	1,423,122			$	3.39	Outstanding at December 31, 2012		1,749,868		$	3.03

								STOCK OPTIONS:	Number of shares			Weighted average exercise price
								STOCK OPTIONS:	Number of shares			per share
								Outstanding at December 31, 2010		5,557		$	20.25
								Granted		-			-
		STOCK OPTIONS:	Number of shares				Weighted average exercise price	Exercised		-			-
		STOCK OPTIONS:	Number of shares				per share	Cancelled or expired		-			-
		Outstanding at December 31, 2011	5,557			$	20.25	Outstanding at December 31, 2011		5,557		$	20.25
		Granted	-				-	Granted		-			-
		Exercised	-				-	Exercised		-			-
		Cancelled or expired	-				-	Cancelled or expired		-			-
		Outstanding at December 31, 2012	5,557			$	20.25	Outstanding at December 31, 2012		5,557		$	20.25
		Granted	-				-
		Exercised	-				-
		Cancelled or expired	-				-
		Outstanding at June 30, 2013	5,557			$	20.25
Assumptions used in calculations of the Black-Scholes option pricing model for options and warrants
			Six months ended June 30,						Year ended December 31,
			2013		2012				2012			2011
		Risk-free interest rates	-		2.39%			Risk-free interest rates		0.31-2.39	%		0.42-1.60	%
		Expected life	-		3 years			Expected life	3 years			3 years
		Expected dividends	-		0%			Expected dividends		0	%		0	%
		Expected volatility	-		96%			Expected volatility		96-99	%		96-99	%
		Vycor Common Stock fair value	-		$1.88-$3.38			Vycor Common Stock fair value	$	1.88-$4.50		$	3.00-$4.50

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2012
Income Taxes [Abstract]
Summary of loss before taxes
	Loss Before Taxes

		December 31,			December 31,
		2012			2011
	Domestic	$	2,613,733		$	4,455,038
	Foreign		312,477			323,505
		$	2,926,210		$	4,778,543

Summary of deferred tax assets and valuation allowance
		December 31,			December 31,
		2012			2011
	Operating loss carry-forward	$	2,700,000		$	2,100,000
	Deferred tax asset before Valuation allowance		2,700,000			2,100,000
	Valuation allowance		(2,700,000	)		(2,100,000	)
	Net deferred tax asset	$	—		$	—

Formation_and_Business_of_the_1

Formation and Business of the Company (Details)	0 Months Ended	1 Months Ended	6 Months Ended	12 Months Ended
	Aug. 14, 2007	Aug. 31, 2007	Jun. 30, 2013	Dec. 31, 2012
	Unit	Aug. 31, 2007	operation	operation
Formation and Business of the Company (Textual)
Common stock issued in exchange for partnership units	107	16,048
Number of partnership units outstanding	1,122
Number of operation division			2	2

Going_Concern_Details

Going Concern (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
Going Concern (Details) (USD $)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Jan. 01, 2013	Dec. 31, 2010
Going Concern (Textual)
Net loss	($647,826)	($797,734)	($1,310,498)	($1,581,164)	($2,926,210)	($4,778,541)
Working capital deficit	3,935,428		3,935,428		3,095,031
Stockholders' deficit	-2,408,465		-2,408,465		-1,457,650	875,324		88,714
Cash and cash equivalents	$20,173	$169,657	$20,173	$169,657	$59,821	$950,841	$59,821	$127,081

Business_Acquisition_Details

Business Acquisition (Details) (USD $)	Jan. 04, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2012
Business Acquisition (Details) (USD $)	Jan. 04, 2012	Trademarks and Tradenames [Member]	Patents [Member]	Internally Developed Software [Member]	Other Net Assets [Member]
Purchase price allocation to estimated fair value of the assets acquired and liabilities assumed
Purchase Price Allocation, Gross	$664,054	$121,157	$180,183	$363,472	($758)
Negative Goodwill on acquisition	-66,394
Business Acquisition, Cost of Acquired Entity, Purchase Price	$597,660

Business_Acquisition_Details_T

Business Acquisition (Details Textual)	1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 31, 2012	Jan. 31, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2011	Jan. 04, 2012	Jan. 04, 2012
	USD ($)	GBP (£)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	GBP (£)	USD ($)	USD ($)	GBP (£)
Business Acquisition (Textual)
Purchase price										$597,660
Cash for the acquisition of Sight Science Limited										310,660	200,000
Cash paid at closing							155,330	100,000
Cash to be paid to the Sight Science shareholders on the one-year anniversary of the closing										155,330	100,000
Pre-split restricted shares subject of lock-up agreements	95,667	95,667
Post-split restricted shares subject of lock-up agreements	14,350,000	14,350,000
Restricted shares value	287,000	184,768
Negative Goodwill on Acquisition of Subsidiary						-66,394	-66,394
Transaction costs in connection with the acquisition							18,285
Business acquisition, pro forma revenue									1,001,624
Business acquisition, pro forma net loss									-4,743,324
Business acquisition, pro forma net loss per share									($0.90)
Deferred consideration other liabilities, current							$161,530

Significant_Accounting_Policie3

Significant Accounting Policies (Details)	6 Months Ended		12 Months Ended
Significant Accounting Policies (Details)	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Potential shares of common stock that are not included in the calculation of diluted net loss per share
Potential shares of common stock that are not included in the calculation of diluted net loss per share	2,117,414	2,783,209	2,706,390	3,052,012
Stock options [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share
Potential shares of common stock that are not included in the calculation of diluted net loss per share	5,557	5,557	5,557	5,557
Warrants to purchase common stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share
Potential shares of common stock that are not included in the calculation of diluted net loss per share	1,423,123	1,745,207	1,749,874	1,747,347
Debentures convertible into common stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share
Potential shares of common stock that are not included in the calculation of diluted net loss per share	368,727	368,726	368,726	368,726
Preferred shares convertible into common stock [Member]
Potential shares of common stock that are not included in the calculation of diluted net loss per share
Potential shares of common stock that are not included in the calculation of diluted net loss per share	320,007	663,719	582,233	930,382

Significant_Accounting_Policie4

Significant Accounting Policies (Details Textual) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended		1 Months Ended	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Nov. 30, 2010	Dec. 31, 2012	Dec. 31, 2012
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	NovaVision [Member]	Sight Science Limited [Member]	Software [Member]
Accounting Policies (Textual)
Useful life of patent									5 years
Acquired Finite-lived Intangible Asset, Amount							$540,000	$363,472
Research and development	21,285	45,860	52,635	70,547	126,042	115,665
Capitalized software development cost

Notes_Payables_Details

Notes Payables (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Components of notes payable
Total Notes Payable:	$2,610,198	$2,195,502	$1,636,125
Convertible debentures issued on December 29, 2009 and February 3, 2010 [Member]
Components of notes payable
Total Notes Payable:	441,362	441,362	441,362
Convertible debentures issued on September 30, 2010 and October 14, 2010 [Member]
Components of notes payable
Total Notes Payable:	175,000	175,000	175,000
Debentures payable issued on October 26, 2010 and November 15, 2010 [Member]
Components of notes payable
Total Notes Payable:	400,000	400,000	400,000
Convertible debenture issued on November 15, 2010 [Member]
Components of notes payable
Total Notes Payable:	300,000	300,000	300,000
Term notes issued on March 25, 2011[Member]
Components of notes payable
Total Notes Payable:	300,000	300,000	300,000
Short term, unsecured notes payable issued on July to December 2012 [Member]
Components of notes payable
Total Notes Payable:	300,900	300,900
Short term, unsecured notes payable issued on August to December 2012 [Member]
Components of notes payable
Total Notes Payable:	115,550	115,500
Short term, unsecured notes payable issued on August to December 2012 [Member] 1
Components of notes payable
Total Notes Payable:	98,550	98,550
Short term, unsecured notes payable issued September 2012 [Member]
Components of notes payable
Total Notes Payable:	42,900	42,900
Short term, unsecured notes payable issued on January to June 2013 [Member]
Components of notes payable
Total Notes Payable:	234,225
Short term, unsecured notes payable issued on January to June 2013 [Member] 1
Components of notes payable
Total Notes Payable:	190,000
Unsecured loans [Member]
Components of notes payable
Total Notes Payable:			10,660
Insurance policy finance agreements [Member]
Components of notes payable
Total Notes Payable:	$11,711	$21,290	$9,103

Notes_Payables_Details_Textual

Notes Payables (Details Textual)

Dec. 31, 2012

Dec. 31, 2011

Feb. 03, 2010

Dec. 29, 2009

Jun. 30, 2013

Oct. 31, 2010

Sep. 30, 2010

Jun. 30, 2013

Oct. 14, 2010

Nov. 15, 2010

Nov. 30, 2010

Oct. 26, 2010

Oct. 31, 2010

Jun. 30, 2013

Nov. 15, 2010

Nov. 30, 2010

Jun. 30, 2013

Dec. 20, 2012

Dec. 20, 2010

Mar. 25, 2011

Mar. 31, 2011

Jun. 30, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2013

USD ($)

EUR (€)

Convertible debentures issued on December 29, 2009 and February 3, 2010 [Member]

Convertible debentures issued on September 30, 2010 and October 14, 2010 [Member]

Debentures payable issued on October 26, 2010 and November 15, 2010 [Member]

Convertible debenture issued on November 15, 2010 [Member]

Term notes issued on March 25, 2011[Member]

Short term, unsecured notes payable issued on July to December 2012 [Member]

Short term, unsecured notes payable issued on August to December 2012 [Member]

Short term, unsecured notes payable issued on August to December 2012 [Member] 1

Short term, unsecured notes payable issued September 2012 [Member]

Short term, unsecured notes payable issued on January to June 2013 [Member]

Short term, unsecured notes payable issued on January to June 2013 [Member] 1

Insurance policy finance agreements [Member]

USD ($)

Notes Payable (Textual)

Issuance of convertible debentures

$70,000

$371,362

$85,000

$90,000

$322,500

$77,500

$350,000

$300,900

$115,500

$98,550

$42,900

$234,225

$190,000

$18,737

Term notes payables

300,000

Percentage of company's common stock hold by beneficial owner

50.00%

Interest rate on debentures

6.00%

Conversion price

$1.88

$2.63

$2.85

$4.50

Repayment of convertible debt

50,000

Interest rate on term notes

16.00%

Number of common stock purchased by issuance of warrants

400,000

Exercise price of warrants

$4.50

Period of warrants

3 years

Debt instrument, maturity date, description

Due on demand or one year after the issue date.

Debt instruments, original maturity date

31-Aug-10

31-Aug-11

31-Dec-12

25-Jun-11

Debt instruments, extended maturity date description

Due date has been extended over time to December 31, 2013.

Due date has been extended over time to December 31, 2013

Due date has been extended over time to December 31, 2013.

The due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company at the conversion price of $4.50 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended over time to March 31, 2013

Due date for this note has been extended over time to September 30, 2013.

The notes are due on demand or one year after the issue date

Remaining balance of unsecured debt

8,250

Amount of notes payable secured by first security interest

1,316,362

Repayments od insurance policy

$28,236

Segment_Reporting_Geographical2

Segment Reporting Geographical Information (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Revenue:
Total Revenue	$234,954	$265,386	$466,628	$697,987	$1,205,263	$971,367
Gross Profit:
Total Gross Profit	207,060	225,138	408,716	578,318	1,025,733	795,109
Total Assets:
Total Assets	2,200,081		2,200,081		2,561,160	3,571,640
Vycor Medical [Member]
Revenue:
Total Revenue	146,358	138,239	277,024	460,021	770,676	548,463
Gross Profit:
Total Gross Profit	135,152	118,206	251,431	378,795	668,729	439,422
Total Assets:
Total Assets	859,185		859,185		1,055,026	2,068,084
NovaVision [Member]
Revenue:
Total Revenue	88,596	127,147	189,604	237,966	434,587	422,904
Gross Profit:
Total Gross Profit	71,908	106,932	157,285	199,523	357,004	355,687
Total Assets:
Total Assets	$1,340,896		$1,340,896		$1,506,134	$1,503,556

Segment_Reporting_Geographical3

Segment Reporting, Geographical Information (Details 1) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Revenue:
Total Revenue	$234,954	$265,386	$466,628	$697,987	$1,205,263	$971,367
Gross Profit:
Total Gross Profit	207,060	225,138	408,716	578,318	1,025,733	795,109
Total Assets:
Total Assets	2,200,081		2,200,081		2,561,160	3,571,640
United States [Member]
Revenue:
Total Revenue	180,792	205,602	360,307	567,850	952,256	740,967
Gross Profit:
Total Gross Profit	161,140	172,994	317,328	463,764	810,809	607,702
Total Assets:
Total Assets	1,650,219		1,650,219		1,935,638	3,470,993
Europe [Member]
Revenue:
Total Revenue	54,162	59,784	106,321	130,137
Gross Profit:
Total Gross Profit	45,920	52,144	91,388	114,554
Total Assets:
Total Assets	549,862		549,862		625,523
SINGAPORE
Revenue:
Total Revenue					253,007	230,400
Gross Profit:
Total Gross Profit					214,924	194,651
Germany [Member]
Total Assets:
Total Assets					$85,227	$100,647

Segment_Reporting_Geographical4

Segment Reporting, Geographical Information (Details Textual)	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
	Segment	Segment
Segment Reporting Geographical Information (Textual)
Number of business segments	2	2
Number of geographic segments	2	2

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)

Jun. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Machinery and equipment [Member]

Leasehold Improvements [Member]

Software [Member]

Molds and Tooling [Member]

Furniture and Fixtures [Member]

Therapy Devices [Member]

Internally Developed Software [Member]

Summary of property and equipment and the estimated lives

Estimated Useful Lives

3 years

5 years

3 years

5 years

7 years

3 years

5 years

Property and Equipment, Gross

$1,402,885

$995,704

$123,355

$106,368

$6,206

$17,833

$15,607

$234,230

$21,533

$21,130

$76,513

$59,065

$923,215

$559,304

Less: Accumulated depreciation and amortization

-575,496

-324,413

Property and equipment, net

$721,777

$827,389

$671,291

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	6 Months Ended		12 Months Ended
Property and Equipment (Details Textual) (USD $)	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Property and Equipment (Textual)
Depreciation of fixed assets	$126,512	$123,320	$247,156	$161,284
Depreciation allocated to cost of sales			$22,610	$16,725

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Intangible assets not subject to amortization
Trademarks	$251,157	$251,157	$130,000
Patents [Member]
Amortized intangible assets:
Gross carrying Amount		705,662	492,147
Accumulated Amortization		-202,767	-112,568
Net carrying Amount		502,895	379,579
Website [Member]
Amortized intangible assets:
Gross carrying Amount		18,909	18,909
Accumulated Amortization		-16,137	-14,003
Net carrying Amount		$2,772	$4,906

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	6 Months Ended		12 Months Ended
Intangible Assets (Details Textual) (USD $)	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Intangible Assets (Textual)
Amortization of intangible assets	$62,844	$51,546	$104,344	$69,022
Patents [Member]
Intangible Assets (Textual)
Useful life of patent			8 years
Website [Member]
Intangible Assets (Textual)
Useful life of patent			5 years

Equity_Details

Equity (Details) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

2 Months Ended

8 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

2 Months Ended

6 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Jan. 15, 2013

Mar. 02, 2011

Mar. 31, 2013

Apr. 30, 2011

Dec. 31, 2011

Jun. 30, 2013

Dec. 31, 2012

Nov. 30, 2012

Sep. 30, 2011

Feb. 10, 2010

Dec. 11, 2011

Jun. 06, 2011

Jul. 31, 2011

Aug. 26, 2011

Jan. 31, 2012

31-May-11

Feb. 28, 2011

Dec. 31, 2012

Jun. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2013

Dec. 31, 2012

Jun. 30, 2012

Aug. 31, 2012

Apr. 30, 2012

Dec. 31, 2011

31-May-13

Jun. 30, 2013

Nov. 30, 2012

31-May-13

Jun. 30, 2013

Sep. 30, 2011

Jun. 03, 2011

Jun. 25, 2011

Apr. 30, 2011

Jun. 06, 2011

Feb. 10, 2010

Aug. 31, 2011

Sep. 30, 2011

Nov. 30, 2012

Jul. 31, 2011

Mar. 25, 2011

Jun. 30, 2011

Jun. 30, 2013

Dec. 31, 2012

Mar. 02, 2011

Apr. 30, 2011

Jun. 07, 2011

Dec. 11, 2011

Jun. 28, 2011

Jul. 31, 2011

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

Consulting Agreement [Member]

Placement Agent Agreement [Member]

Consulting and Advisory Services [Member]

Series C Convertible Preferred Stock Purchase Agreements [Member]

Restricted Stock [Member]

Common Stock [Member]

Term Loan [Member]

Debenture [Member]

Series C Preferred Stock [Member]

Stock Warrant [Member]

Initial Closing [Member]

Second Closing [Member]

Final Closing [Member]

First Closing, Second Closing and Final Closing [Member]

Dr Oscar Bronsther [Member]

Fountainhead Capital Partners Limited [Member]

Burnham Hill Partners Llc [Member]

Millennium Capital Corporation [Member]

Prof. Sahraie and the University of Aberdeen [Member]

Investor

Steven Girgenti [Member]

Dr Oscar Bronsther [Member]

Alvaro Pascual - Leone [Member]

Jason Barton [Member]

Jose Romano [Member]

Josef Zihl [Member]

Greenbridge Capital Partners Iv Llc [Member]

Mr. Jerrald Ginder [Member]

Brunella Jacs, LLC [Member]

Fountainhead Capital Partners Limited [Member]

Alvaro Pasual-Leone, Jason Barton and Jose Romano [Member]

Fiducuary Foundation [Member]

Kenneth Coviello [Member]

Heather Vinas [Member]

Investors [Member]

Lowell Rush [Member]

Consulting Agreement [Member]

Consulting and Advisory Services [Member]

Consulting Agreement [Member]

Berardino Investment Group [Member]

Party

Series C Convertible Preferred Stock Purchase Agreements [Member]

Investor

Dr Oscar Bronsther [Member]

Greenbridge Capital Partners Iv Llc [Member]

Mr. Jerrald Ginder [Member]

Burnham Hill Advisors Llc [Member]

Fountainhead Capital Partners Limited [Member]

Mccombie Group Llc [Member]

Joe Simone [Member]

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

Millennium Capital Corporation [Member]

EuroAmerican Investment Corp [Member]

Equity (Textual)

Number of related parties

1,078

Share-based compensation shares issued to nonemployees for services, share

95,667

57,779

50,527

50,372

4,114

5,928

5,920

4,787

5,928

645

1,594

3,704

1,217

3,704

926

3,704

926

2,261

2,778

137,778

8,889

2,319

14,815

2,500

103,334

17,778

120,000

6,667

2,858

3,400

140,000

93,334

162,965

Share-based compensation shares issued to nonemployees for services, value

$157,500

$10,500

$195,000

$144,000

$170,000

$10,000

$20,000

$10,000

$20,000

$2,174

$4,688

$12,500

$6,250

$12,500

$6,250

$12,500

$6,250

$9,375

$30,000

$4,688

$16,667

$348,750

$60,000

$360,000

$22,500

$10,000

$157,500

$105,000

$550,000

Share based compensation shares issued to nonemployees per share value

$2.85

$3.38

Number of common stock issuable upon conversion of warrants issued

98,070

81,842

24,682

25,719

28,889

2,667

260,425

15,334

2,667

232,593

114,074

97,778

444,444

Number of common stock issuable upon conversion of each warrants issued

7,408

Value of common stock issuable upon conversion of warrants issued

$4.50

$1.88

$4.50

Warrants expiration period

3 years

5 years

3 years

Debt amount

300,000

40,000

Debt discount amortization period

3 months

Number of units issued in preferred offering

24.8

3.8

31.4

15.4

13.2

Proceeds from units issued

190,000

1,570,000

770,000

660,000

3,000,000

Maximum proceeds allowed under agreement

3,000,000

Convertible preferred stock, shares issuable upon conversion of each unit

14,815

Convertible preferred stock, shares issuable upon conversion

465,186

228,149

195,556

888,889

Convertible preferred stock, shares issuable upon conversion, per share

$3.38

Price of Units (Units comprising Series C Convertible Preferred Shares and Warrants)

$50,000

Number of units rescinded

Amount returned due to cancellation of units

50,000

Escrow shares subject to clawback option

68,889

Exercise period of clawback option

Exerciseable in equal tranches by April 15 and 30, 2012

Percentage gross proceeds paid to placement agent

7.00%

Percentage of number of common stock issuable upon conversion

7.00%

Conversion price

$2.85

Stock converted into Common Stock

2,687

14,453

348,152

Common stock issuance for conversion of debt

41,190

443.26

Consultancy agreement term

12 months

Shares repurchased into Treasury Stock

34,445

68,889

Treasury stock repurchased, value

1,033.33

Effect of reverse stock split

1 for 150

Common Stock, par value (in dollars per share)

$0.00

Number of common shares prior to reverse split

892,749,897

Reduction in number of shares as of stock split

5,951,744

Number of common shares issued for round up of partial shares

Shares repurchased into Treasury Stock from GreenBridge Capital Partner

34,445

68,889

Warrant exercise price

3.38

1.88

1.08

0.1

Warrants issued/sold to purchase shares of common stock

162,250

Shares issued upon exercise of warrant

47,590

32,152

162,250

Number Of Investor

Proceeds from exercise of warrants

$304,351

Common stock issued upon conversion of preferred stock

262,229

ShareBased_Compensation_Detail

Share-Based Compensation (Details) (USD $)	6 Months Ended	12 Months Ended
Share-Based Compensation (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock Warrant [Member]
Details of the outstanding rights, options and warrants and value of such rights, options and warrants
Options Outstanding, Beginning Balance	1,749,874	1,747,341	777,371
Number of Shares, Granted		4,667	987,869
Number of Shares, Exercised	-326,752		-2,687
Number of Shares, Cancelled or expired		-2,140	-15,212
Options Outstanding, Ending Balance	1,423,122	1,749,868	1,747,341
Weighted average exercise price per share, Outstanding, Beginning Balance	$3.03	$3.07	$2.35
Weighted average exercise price per share, Granted		$4.50	$3.78
Weighted average exercise price per share, Exercised	$1.47		$0.17
Weighted average exercise price per share, Cancelled or expired		$36	$12.96
Weighted average exercise price per share, Outstanding, Ending balance	$3.39	$3.03	$3.07
Stock options [Member]
Details of the outstanding rights, options and warrants and value of such rights, options and warrants
Options Outstanding, Beginning Balance	5,557	5,557	5,557
Number of Shares, Granted
Number of Shares, Exercised
Number of Shares, Cancelled or expired
Options Outstanding, Ending Balance	5,557	5,557	5,557
Weighted average exercise price per share, Outstanding, Beginning Balance	$20.25	$20.25	$20.25
Weighted average exercise price per share, Granted
Weighted average exercise price per share, Exercised
Weighted average exercise price per share, Cancelled or expired
Weighted average exercise price per share, Outstanding, Ending balance	$20.25	$20.25	$20.25

ShareBased_Compensation_Detail1

Share-Based Compensation (Details 1) (USD $)	6 Months Ended		12 Months Ended
Share-Based Compensation (Details 1) (USD $)	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Options and warrants expensed
Risk Free Interest Rate		2.39%
Risk Free Interest Rate, Minimum			0.31%	0.42%
Risk Free Interest Rate, Maximum			2.39%	1.60%
Expected life		3 years	3 years	3 years
Expected dividends		0.00%	0.00%	0.00%
Expected volatility		96.00%
Expected volatility Minimum			96.00%	96.00%
Expected volatility Maximum			99.00%	99.00%
Vycor Common Stock fair value minimum		$1.88	$1.88	$3
Vycor Common Stock fair value maximum		$3.38	$4.50	$4.50

ShareBased_Compensation_Detail2

Share-Based Compensation (Details Textual)

1 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

6 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

6 Months Ended

Jan. 31, 2012

Jun. 30, 2013

Jun. 30, 2012

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Jun. 30, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Mar. 31, 2011

Dec. 31, 2012

Jun. 30, 2011

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2012

Apr. 30, 2012

Sep. 30, 2012

Nov. 30, 2012

Dec. 31, 2012

Nov. 30, 2012

Dec. 31, 2012

Jun. 30, 2013

31-May-10

Feb. 29, 2008

Dec. 31, 2012

Dec. 31, 2011

Feb. 29, 2008

31-May-10

Feb. 29, 2008

Feb. 28, 2010

Dec. 31, 2012

Feb. 10, 2010

31-May-10

Jun. 30, 2013

USD ($)

GBP (£)

USD ($)

Stock options [Member]

Stock Warrant [Member]

Steven Girgenti [Member]

Dr Oscar Bronsther [Member]

Alvaro Pascual - Leone [Member]

Jason Barton [Member]

Jose Romano [Member]

Mr. Jerrald Ginder [Member]

GreenBridge Capital Partners [Member]

Josef Zihl [Member]

Brunella Jacs, LLC [Member]

OneSource [Member]

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

Board of Directors Chairman [Member]

Scientific Advisory Board [Member]

Stock Option Plan [Member]

Non Employee Stock Compensation [Member]

Consulting Agreement [Member]

USD ($)

Common Stock [Member]

USD ($)

Common Stock [Member]

USD ($)

Common Stock [Member]

USD ($)

Common Stock [Member]

USD ($)

Common Stock [Member]

USD ($)

Common Stock [Member]

USD ($)

Common Stock [Member]

USD ($)

Common Stock [Member]

USD ($)

Stock Warrant [Member]

USD ($)

Chief Executive Officer [Member]

President [Member]

USD ($)

Steven Girgenti [Member]

Dr Oscar Bronsther [Member]

Alvaro Pascual - Leone [Member]

Jason Barton [Member]

Jose Romano [Member]

Josef Zihl [Member]

Lowell Rush [Member]

USD ($)

Share Based Compensation (Textual)

Ownership percentage of outstanding voting stock for the options to be granted

More than 10

Exercise price of options granted

Not less than 110% of the fair market value of the common stock on the grant date

Option expired period determined by the board of directors

Not extend more than 10 years from the grant date

Outstanding voting stock expire from grant date

5 years

Vesting period for employees

3 years

Number of Shares, Granted

4,667

987,869

500,000

Percentage of number of shares covered by plan

10.00%

Exercise price per share

$4.50

$3.78

$0.14

Percentage of options vested on first anniversary

33.33%

Percentage of options vested on second anniversary

33.33%

Percentage of options vested on third anniversary

33.33%

Grant expire date

12-Feb-18

Share-based compensation arrangement, cancelled or expired in Period

667

166,667

Share based compensation expenses

$174,063

$30,000

$46,875

$109,570

$116,250

$2,906

$113,344

$46,875

$30,000

$21,875

$22,500

$20,312

$20,397

$131,250

Weighted-average remaining contractual life of outstanding options

4 years 7 months 17 days

5 years 1 month 13 days

1 year 4 months 28 days

1 year 11 months 5 days

Common stock purchased by the related party

260,425

Fair value of common stock

$1.88

$4.50

$1.88

Validity of warrants

5 years

Share-based compensation shares issued to nonemployees for services, share

5,928

3,704

2,778

8,889

4,114

4,787

1,594

2,319

2,261

1,078

Share-based compensation shares issued to nonemployees for services, value

157,500

20,000

12,500

348,750

9,375

30,000

157,500

10,500

280,331

10,000

4,688

6,250

2,500

Maximum common stock receivable under the agreement

Common stock received under the agreement

103,334

consultancy agreement period

12 months

1 year

3 years

12 months

Restricted Shares Issued

137,778

Restricted shares value

287,000

184,768

420,000

Options to repurchase common shares

68,889

Total unrecognized compensation costs related to warrant and stock awards and non-vested options

107,375

240,625

Warrant received by OneSource

4,667

Fair value of warrant

$8,708

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
Income Taxes (Details) (USD $)	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Summary of loss before taxes
Domestic					$2,613,733	$4,455,038
Foreign					312,477	323,505
Net loss	($647,826)	($797,734)	($1,310,498)	($1,581,164)	($2,926,210)	($4,778,541)

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Dec. 31, 2012	Dec. 31, 2011
Summary of deferred tax assets and valuation allowance
Operating loss carry-forward	$2,700,000	$2,100,000
Deferred tax asset before Valuation allowance	2,700,000	2,100,000
Valuation allowance	-2,700,000	-2,100,000
Net deferred tax asset

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
Income Taxes (Details Textual) (USD $)	Dec. 31, 2012	Dec. 31, 2011
Income taxes (Textual)
Percentage appropriation of valuation allowance as decided by management	100.00%	100.00%
U.S. federal [Member]
Income taxes (Textual)
Net operating loss carryforwards	$7,600,000	$6,000,000
Operating loss carryforwards expiry date	2027 through 2031.
Income tax rate	35.00%	35.00%
German Tax Authority [Member]
Income taxes (Textual)
Net operating loss carryforwards	490,000	450,000
Income tax rate	35.00%	35.00%
UK tax authority [Member]
Income taxes (Textual)
Net operating loss carryforwards	$100,000	$0
Income tax rate	24.00%	24.00%

Commitments_and_Contingencies_

Commitments and Contingencies (Details)	1 Months Ended			6 Months Ended		12 Months Ended
	Aug. 31, 2012	Jun. 30, 2012	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2012	Dec. 31, 2011
		USD ($)	EUR (€)	USD ($)	USD ($)	USD ($)	EUR (€)	USD ($)
				sqft		sqft
Commitments and Contingencies (Textual)
Area of leased building (sq. ft)				10,000		10,000	10,000
Rent expenses plus sales tax (per month)				$14,260		$14,260
Term of lease				5 years 6 months		5 years 6 months	5 years 6 months
Lease expiration date				31-Jul-17		31-Jul-17	31-Jul-17
Approximate preliminary assessed trade tax		94,000	75,000
Approximate preliminary assessed corporate tax		0	0
Provision for advisory fees statutory, minimum						50,105	39,000
Description of Food and Drug Administration	The FDA was notified and all customers with units that had been distributed (a total of 5 customers in the U.S. and 2 customers internationally) were contacted and the units were recalled and replaced with re-inspected and passed units, or internationally re-inspected under 100% enhanced inspection guidelines; this recall and replacement process was completed in November 2012 and there are no affected units on the marketplace.			The FDA was notified and all customers with units that had been distributed (a total of 5 customers in the U.S. and 2 customers internationally) were contacted and the units were recalled and replaced with re-inspected and passed units, or internationally re-inspected under 100% enhanced inspection guidelines; this recall and replacement process was completed in the US in September 2012 and internationally in November 2012 and there are no affected units on the marketplace.
Rent expense				$96,444	$96,367	$190,023		$180,255

Consulting_and_Other_Agreement1

Consulting and Other Agreements (Details) (USD $)

6 Months Ended

12 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Jun. 30, 2013

Jun. 30, 2012

Dec. 31, 2012

Dec. 31, 2011

Mar. 31, 2011

Sep. 30, 2012

Mar. 31, 2011

Feb. 28, 2010

Jun. 30, 2012

Jun. 03, 2011

Jul. 31, 2011

14-May-12

Nov. 30, 2012

Mr. Jerrald Ginder [Member]

Fountainhead [Member]

GreenBridge Capital Partners [Member]

Partizipant, LLC [Member]

OneSource Advisors, LLC [Member]

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

Del Mar Consulting Group, Inc and Alex Partners, Llc [Member]

Restricted Stock [Member]

Consulting and Other Agreements (Textual)

Consulting agreement duration

1 year

3 months

12 months

Share-based compensation shares issued to nonemployees for services, value

$157,500

$105,000

Shares received under consulting agreement, shares

137,778

Cash payment pursuant to consulting agreement

7,200

4,800

Shares received under consulting agreement, value

420,000

103,334

157,500

105,000

Share based compensation and expense

174,064

204,755

297,004

1,760,545

Payment of monthly retainer under consulting agreement

37,500

Payment made in original agreement for consultancy services

8,500

Payment made in supplement agreement for consultancy services

29,000

Description of accrued and paid of consulting fee at the option of consultant

(i) in Vycor stock or (ii) in cash following the closing of a fundraising of no less than $2.5 million or on the sale of the Company or a substantial part of the assets thereof at any time after June 30, 2011.

Maximum cash payment for consulting services (monthly)

5,000

Share price under original agreement

$1.88

Maximum common stock receivable under the agreement

2,500,000

Share price under supplement

$3.38

Consulting agreement maturity date

1-Apr-12

5-May-13

Stock returned to company and retired, shares

137,778

34,445

Value of common shares repurchased

1,033.33

Options to repurchase common shares

68,889

Number of shares that are no longer subject of repurchase option

34,445

One time payment for consulting services

$300,000

Warrant received to purchase maximum common shares

4,667

Warrant received to purchase maximum common shares, price per share

$4.50

Warrant exercise period to purchase common stock

3 years

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)

6 Months Ended

2 Months Ended

6 Months Ended

1 Months Ended

12 Months Ended

Jun. 30, 2013

Jun. 30, 2012

Nov. 30, 2012

31-May-13

Dec. 31, 2012

Mar. 31, 2013

Jun. 30, 2012

Mar. 31, 2013

Dec. 31, 2012

Mar. 31, 2013

Jun. 30, 2013

Apr. 30, 2013

Nov. 30, 2012

Dec. 31, 2012

Secured Loan One [Member]

Secured Loan Two [Member]

Fountainhead [Member]

Peter Zachariou [Member]

Heather Vinas [Member]

Secured Loan One [Member]

Subsequent Event [Member]

Related Party Transaction (Textual)

Loan amount

$1,016,362

$300,000

$309,900

$1,016,362

$234,225

$90,000

$115,550

$300,000

$190,000

Secured loan notes, interest rate

6.00%

Secured loan notes, due date

Due on demand or by their one-year anniversary

Warrants issue to purchase an additional shares to fully vested

54,834

Extended maturity date of secured loans

From March 31, 2013 to December 31, 2013.

Warrants issue to purchase additional shares to fully vested Common stock price

$2.60

$0.87

Number of warrants exercisable on first day each month

4,570

Common stock receive upon exercise of warrant

32,152

Common stock held

66,272

Restriction on sale of common stock

The Agreement also requires Mrs Vinas not to sell more than 16,000 shares in any 30-day period.

Warrants sold to purchase shares

162,250

Warrant exercise price

$1.88

Warrant sale price

$0.10

Subsequent_Events_Details

Subsequent Events (Details) (USD $)

0 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

2 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

2 Months Ended

0 Months Ended

1 Months Ended

Jan. 15, 2013

Jun. 30, 2013

Dec. 31, 2011

Dec. 31, 2012

Nov. 30, 2012

Jul. 02, 2013

Jan. 15, 2013

Jul. 31, 2013

Jan. 31, 2013

Jul. 31, 2013

Jan. 31, 2013

Jul. 31, 2013

Jan. 31, 2013

Aug. 31, 2013

Mar. 31, 2013

Jun. 30, 2012

Jun. 03, 2011

Mar. 31, 2013

Jan. 31, 2013

Jan. 01, 2013

Oct. 12, 2012

Nov. 30, 2012

Aug. 09, 2013

Nov. 30, 2012

Aug. 09, 2013

Aug. 31, 2013

Jul. 02, 2013

Jul. 31, 2013

Secured Loan One [Member]

Secured Loan Two [Member]

Subsequent Event [Member]

Steven Girgenti [Member]

Dr Oscar Bronsther [Member]

Alvaro Pasual Leone [Member]

Josef Zihl [Member]

Fountainhead [Member]

Peter Zachariou [Member]

GreenBridge Capital Partners [Member]

Kenneth T Coviello [Member]

Heather Vinas [Member]

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

Craig Kirsch [Member]

Advisory Agreement [Member]

Placement Agent Agreement [Member]

Scientific Advisory Board [Member]

Agreements

Subsequent Event [Member]

Secured Loan One [Member]

Secured Loan Two [Member]

Issuance of Equity [Member]

Subsequent Events (Textual)

Shares issued for services, value

$5,000

$1,563

$3,125

$103,334

$157,500

$105,000

Shares issued for services, shares

2,155

1,482

659

1,319

7,200

4,800

15,000

Shares issued on conversion of Preferred C stock, shares

7,408

Common stock issuance for conversion of debt, shares

926

Common stock issuance for conversion of debt

41,190

3,125

Common Stock, par value (in dollars per share)

$0.00

Number of agreements

Reverse stock split , shares converted

1 for 150

1 for 150 share

Number of common shares prior to reverse split

892,749,897

Reduction in number of shares as of stock split

5,951,744

Number of common shares issued for round up of partial shares

Loan amount

$1,016,362

$300,000

$90,000

$130,000

$1,016,362

$300,000

$145,000

$10,000

Secured loan notes, interest rate

6.00%

Stock returned to company and retired, shares

34,445

Warrant issued to purchase maximum common stock, shares

109,668

54,834

Warrant issued to purchase maximum common stock, per share price

$0.87

Option exercise related to warrants

27,417

Option exercise related to warrants on monthly basis

9,139

4,570

Option exercise period related to warrant

9 months

Description of agreement

The broker-dealer is engaged on a non-exclusive basis to provide financial advisory services to the Company for at least ninety (90) days and thereafter until either party terminates the arrangement.

The Company engaged a broker-dealer as its exclusive placement agent until the later of (i) 90 days from the date of execution of the Agreement or (ii) the end of the offering period of any securities financing undertaken by the Company in connection with the Placement Agent Agreement.

Restricted shares of common stock issuable under the agreement

60,000

Restricted shares of common stock issuable on date of execution

15,000

Additional shares issued on monthly basis from 7th month onwards

7,500